Factor IX Polypeptide Preparations

A factor IX polypeptide fused to an FcRn binding partner, combined with specific excipients, addresses the challenges of short half-life in current treatments by providing long-acting factor IX activity, improving treatment efficacy and compliance in hemophilia B.

JP7591866B2Active Publication Date: 2024-11-29BIOVERATIV THERAPEUTICS INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2019188574
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2013-03-15
Filing Date
2019-10-15
Publication Date
2024-11-29
Estimated Expiration
2034-03-14

AI Technical Summary

Technical Problem

Current treatments for hemophilia B, caused by factor IX deficiency, are limited by the difficulty in purifying factor IX from plasma, the presence of infectious agents, and the short half-life of recombinant factor IX, requiring frequent dosing and higher doses for efficacy.

Method used

A pharmaceutical composition comprising a factor IX polypeptide fused to an FcRn binding partner (rFIXFBP) with a carbohydrate mixture, including sucrose and mannitol, sodium chloride, L-histidine, and polysorbate, formulated to provide long-acting factor IX activity, reducing the frequency of administration.

Benefits of technology

The composition extends the duration of factor IX activity, allowing for less frequent dosing and improved prophylaxis and treatment of bleeding episodes in hemophilia B patients, enhancing compliance and reducing joint damage and morbidity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591866000001
    Figure 0007591866000001
  • Figure 0007591866000002
    Figure 0007591866000002
  • Figure 0007591866000003
    Figure 0007591866000003
Patent Text Reader

Abstract

To provide Factor IX polypeptide formulations.SOLUTION: The present invention relates to formulations comprising a Factor IX-FcRn Binding Partner (FIXFBP) polypeptide, and to methods of administering FIXFBP. A pharmaceutical composition comprises: (a) a Factor IX polypeptide comprising human Factor IX fused to an FcRn binding partner (FBP) (rFIXFBP polypeptide), where the polypeptide has long-acting Factor IX activity; (b) a carbohydrate mixture comprising sucrose and mannitol; (c) sodium chloride (NaCl); (d) L-histidine; and (e) polysorbate 20 or polysorbate 80.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates generally to the field of treatment of hemostatic disorders. [Background technology]

[0002] Hemophilia B (also known as Christmas disease) is one of the most common inherited bleeding disorders worldwide. It results in reduced blood clotting activity in vivo and in vitro and requires extensive medical monitoring throughout the life of the affected individual. In the absence of intervention, affected individuals will suffer from spontaneous bleeding in joints that results in severe pain and debilitating immobility, bleeding into muscles that results in the accumulation of blood in those tissues, spontaneous bleeding in the throat and neck that can cause asphyxiation if not treated immediately, kidney bleeding, and severe bleeding after surgery, minor accidental injuries, or tooth extraction are also common.

[0003] Normal in vivo blood clotting requires, at a minimum, serine protease II (prothrombin), factors VII, IX and XI (soluble plasma proteins), with cofactors including the transmembrane protein tissue factor and plasma proteins factors V and VIII, fibrinogen, transglutaminase factor XIII, phospholipids (including activated platelets), and calcium. Additional proteins, including kallikrein, high molecular weight kininogen, and factor XII, are required for in vitro clotting tests and may be affected in vivo under diagnostic pathology.

[0004] In hemophilia, blood clotting is hindered by the lack of certain plasma clotting factors. Hemophilia B is caused by factor IX deficiency, which can result either from reduced synthesis of the factor IX protein or from a defective molecule with reduced activity. Hemophilia is treated by replacing the missing clotting factor with exogenous factor concentrates that are highly concentrated in factor IX. However, producing such concentrations from blood is technically difficult, as explained below.

[0005] Purification of factor IX from plasma (plasma-derived factor IX, or pdFIX) almost exclusively results in active factor IX. However, such purification of factor IX from plasma is very difficult, since factor IX is present only at low concentrations in plasma (5 μg / mL; Andersson, Thrombosis Research 7:451 459 (1975)). Furthermore, purification from blood requires the removal or inactivation of infectious agents such as IV and HCV. Moreover, pdFIX has a short half-life and therefore requires frequent administration. Recombinant factor IX (rFIX) is also available, but suffers from a similarly short half-life and requires similar frequent administration as pdFIX (e.g., 2-3 times per week for prophylaxis). rFIX has a lower incremental recovery (K value) compared to pdFIX, necessitating the use of higher doses of rFIX than those of pdFIX. Reduction of mortality, prevention of joint damage and improvement of quality of life are important outcomes of the development of plasma-derived and recombinant factor IX. Long-term protection from bleeding represents another important advance in the treatment of subjects with hemophilia B. However, to date, no product has been developed that allows long-term protection. Thus, there is a need for improved methods of treating hemophilia caused by factor IX deficiency that are more tolerable and more effective than current therapies. [Prior art documents] [Non-patent literature]

[0006] [Non-Patent Document 1] Andersson, Thrombosis Research 7:451 459 (1975) Summary of the Invention [Means for solving the problem]

[0007] The present invention is directed to a pharmaceutical composition comprising: (a) a factor IX polypeptide comprising human factor IX fused to an FcRn binding partner (rFIXFBP polypeptide), the polypeptide having long-acting factor IX activity; (b) a carbohydrate mixture comprising sucrose and mannitol; (c) sodium chloride (NaCl); (d) L-histidine; and (e) polysorbate 20 or polysorbate 80. In one embodiment, the pharmaceutical composition comprises about 1% (w / v) to about 2% (w / v) sucrose (e.g., about 1.2% (w / v) or about 1.7% (w / v) sucrose), or about 10 mg / ml to about 20 mg / ml sucrose (e.g., about 11.9 mg / ml or about 16.7 mg / ml sucrose). In another embodiment, the pharmaceutical composition comprises about 2% (w / v) to about 4% (w / v) mannitol (e.g., about 2.4% (w / v) mannitol or about 3.3% (w / v) mannitol), or about 20 mg / ml to about 40 mg / ml mannitol (e.g., about 23.8 mg / ml mannitol or about 33.3 mg / ml mannitol). In other embodiments, the pharmaceutical composition comprises about 50 mM to about 60 mM NaCl (e.g., about 55.6 mM NaCl), or about 3 mg / ml to about 4 mg / ml NaCl (e.g., about 3.25 mg / ml NaCl). In some embodiments, the pharmaceutical composition comprises about 20 mM to about 40 mM L-histidine (e.g., about 25 mM L-histidine or about 35 mM L-histidine), or about 3 mg / ml to about 6 mg / ml L-histidine (e.g., about 3.88 mg / ml L-histidine or about 5.43 mg / ml L-histidine).In certain embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.020% (w / v) of polysorbate 20 or polysorbate 80 (e.g., about 0.010% (w / v) of polysorbate 20 or polysorbate 80, or about 0.014% (w / v) of polysorbate 20 or polysorbate 80), or about 0.08 mg / ml to about 0.2 mg / ml of polysorbate 20 or polysorbate 80 (e.g., about 0.10% mg / ml of polysorbate 20 or polysorbate 80, or about 0.14 mg / ml of polysorbate 20 or polysorbate 80).

[0008] The pharmaceutical composition can comprise an rFIXFBP polypeptide, which is an rFIXFc polypeptide comprising a first subunit comprising an amino acid sequence at least 90% or 95% identical to amino acids 1 to 642 of SEQ ID NO:2, and a second subunit comprising an amino acid sequence at least 90% to 100% identical to amino acids 1 to 227 of SEQ ID NO:4.

[0009] In some embodiments, an rFIXFBP polypeptide having factor IX activity is present at a concentration of about 25 IU / ml to about 1200 IU / ml (e.g., 50 IU / ml, 100 IU / ml, 200 IU / ml, 400 IU / ml, or 600 IU / ml of rFIXFBP polypeptide).

[0010] In one embodiment, the pharmaceutical composition comprises: (a) about 25 IU / ml to about 700 IU / ml of rFIXFBP polypeptide; (b) about 1% (w / v) to about 2% (w / v) sucrose; (c) about 2% (w / v) to about 4% (w / v) mannitol; (d) about 50 mM to about 60 mM NaCl; (e) about 20 mM to about 40 mM L-histidine; and (f) about 0.008% (w / v) to about 0.015% polysorbate 20 or polysorbate 80. For example, a pharmaceutical composition can include: (a) about 50 IU / ml, about 100 IU / ml, about 200 IU / ml, or about 400 IU / ml of rFIXFBP polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) polysorbate 20 or polysorbate 80.

[0011] In another embodiment, the pharmaceutical composition comprises: (a) about 600 IU / ml of rFIXFBP polypeptide; (b) about 1.7% (w / v) sucrose; (c) about 3.3% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 35 mM L-histidine; and (f) about 0.014% (w / v) polysorbate 20 or polysorbate 80.

[0012] In other embodiments, the pharmaceutical composition comprises: (a) about 25 IU / ml to about 700 IU / ml of rFIXFBP polypeptide; (b) about 10 mg / ml to about 20 mg / ml of sucrose; (c) about 20 mg / ml to about 40 mg / ml of mannitol; (d) about 3 mg / ml to about 4 mg / ml of NaCl; (e) about 3 mg / ml to about 6 mg / ml of L-histidine; and (f) about 0.08 mg / ml to about 0.15 mg / ml of polysorbate 20 or polysorbate 80. For example, the pharmaceutical composition comprises: (a) about 50 IU / ml, about 100 IU / ml, about 200 IU / ml, or about 400 IU / ml of rFIXFBP polypeptide; (b) about 11.9 mg / ml of sucrose; (c) about 23.8 mg / ml of mannitol; (d) about 3.25 mg / ml of NaCl; (e) about 3.88 mg / ml of L-histidine; and (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. In some embodiments, the pharmaceutical composition comprises: (a) about 600 IU / ml of rFIXFBP polypeptide; (b) about 16.7 mg / ml of sucrose; (c) about 33.3 mg / ml of mannitol; (d) about 3.25 mg / ml of NaCl; (e) about 5.43 mg / ml of L-histidine; and (f) about 0.14 mg / ml of polysorbate 20 or polysorbate 80.

[0013] In certain aspects, the present invention is directed to a pharmaceutical kit comprising: (a) a first container comprising a lyophilized powder, the powder comprising (i) an rFIXFBP polypeptide, (ii) sucrose, (iii) mannitol, (iv) L-histidine, and (v) polysorbate 20 or polysorbate 80; and (b) a second container comprising 0.325% (w / v) NaCl in combination with the lyophilized powder in the first container. In one embodiment, the pharmaceutical kit comprises: (a) a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU, about 500 IU, about 1000 IU, or about 2000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80; and (b) a first container containing a lyophilized powder that, when combined with the lyophilized powder in the first container, (i) and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing about 50 IU / ml, about 100 IU / ml, about 200 IU / ml, or about 400 IU / ml of rFIXFBP polypeptide, respectively; (ii) about 1.2% (w / v) sucrose; (iii) about 2.4% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 25 mM L-histidine; and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80.In another embodiment, the pharmaceutical kit comprises: (a) a first container containing a lyophilized powder, the powder comprising: (i) about 3000 IU of rFIXFBP polypeptide; (ii) about 83.3 mg of sucrose; (iii) about 167 mg of mannitol; (iv) about 27.2 mg of L-histidine; and (v) about 0.7 mg of polysorbate 20 or polysorbate 80; and (b) a first container containing a lyophilized powder that, when combined with the lyophilized powder in the first container, and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (i) about 600 IU / ml of rFIXFBP polypeptide; (ii) about 1.7% (w / v) sucrose; (iii) about 3.3% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 35 mM L-histidine; and (vi) about 0.014% (w / v) polysorbate 20 or polysorbate 80.

[0014] In some embodiments, the invention provides a method of administering rFIXFBP polypeptide to a subject with hemophilia B in need of prophylaxis, comprising administering a pharmaceutical composition of the invention intravenously to the subject at an initial dose of about 50 IU / kg once a week, or at an initial dose of about 100 IU / kg once every 10-14 days, whereby the administration prevents or reduces the frequency of bleeding episodes in the subject. In other embodiments, the invention provides a method of administering rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for mild to moderate bleeding episodes, comprising administering a pharmaceutical composition of the invention intravenously to the subject at an initial dose of about 30 IU / kg to about 60 IU / kg, whereby the administration controls, reduces, or reverses the bleeding episodes. The method can further comprise administering one or more doses every 48 hours if the subject shows further signs of bleeding. In yet another aspect, the invention includes a method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for a heavy bleeding episode, comprising administering intravenously to the subject a pharmaceutical composition of the invention at an initial dose of about 100 IU / kg, which administration controls, reduces, or reverses the bleeding episode. In one embodiment, the method further comprises administering a booster dose of the pharmaceutical composition at about 80 IU / kg about 6-10 hours later if the bleeding episode continues. In another embodiment, the method further comprises administering one or more booster doses of the pharmaceutical composition at 80 IU / kg every 24 hours for three days if the bleeding episode continues. In another embodiment, the method further comprises administering one or more booster doses of the pharmaceutical composition at 80 IU / kg every 48 hours until the bleeding episode is controlled.

[0015] In another aspect, the invention includes a method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, comprising administering a pharmaceutical composition of the invention intravenously at a dose of about 50 IU / kg to about 80 IU / kg to a subject with hemophilia B undergoing minor surgery, which administration controls bleeding in the subject during and after surgery. In one embodiment, the method further comprises administering an additional dose of the pharmaceutical composition at about 50 IU / kg to about 48 hours after surgery, if necessary to control post-operative bleeding.

[0016] In yet another aspect, the invention provides a method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, comprising administering a pharmaceutical composition of the invention intravenously at a dose of about 100 IU / kg to a subject with hemophilia B undergoing major surgery, which administration controls bleeding during and after surgery in the subject. In one embodiment, the method further comprises administering an additional dose of the pharmaceutical composition at about 80 IU / kg about 6 to about 10 hours later if post-operative bleeding needs to be controlled. In another embodiment, the method further comprises administering one or more additional doses of the pharmaceutical composition at 80 IU / kg every 24 hours for three days if post-operative bleeding needs to be controlled. In another embodiment, the method further comprises administering one or more additional doses of the pharmaceutical composition at 80 IU / kg every 48 hours if post-operative bleeding needs to be controlled.

[0017] In yet other embodiments, a desired administration of rFIXFBP polypeptides can be obtained from a single pharmaceutical kit of the invention, or from two or more pharmaceutical kits of the invention, the contents of which are pooled prior to administration. In certain embodiments, for example, the following are provided: (Item 1) (a) a factor IX polypeptide comprising a human factor IX fused to an FcRn binding partner (FBP) (rFIXFBP polypeptide), the polypeptide having long-acting factor IX activity; (b) a carbohydrate mixture comprising sucrose and mannitol; (c) sodium chloride (NaCl); (d) L-histidine, (e) polysorbate 20 or polysorbate 80. (Item 2) 2. The pharmaceutical composition according to item 1, comprising about 1% (w / v) to about 2% (w / v) of sucrose. (Item 3) 3. The pharmaceutical composition according to item 2, comprising about 1.2% (w / v) sucrose. (Item 4) 3. The pharmaceutical composition according to item 2, comprising about 1.7% (w / v) sucrose. (Item 5) 2. The pharmaceutical composition according to item 1, comprising about 10 mg / ml to about 20 mg / ml of sucrose. (Item 6) 6. The pharmaceutical composition according to item 5, comprising about 11.9 mg / ml of sucrose. (Item 7) 6. The pharmaceutical composition according to item 5, comprising about 16.7 mg / ml of sucrose. (Item 8) 8. The pharmaceutical composition according to any one of items 1 to 7, comprising about 2% (w / v) to about 4% (w / v) mannitol. (Item 9) 9. The pharmaceutical composition according to item 8, comprising about 2.4% (w / v) mannitol. (Item 10) 9. The pharmaceutical composition according to item 8, comprising about 3.3% (w / v) mannitol. (Item 11) 8. The pharmaceutical composition according to any one of items 1 to 7, comprising about 20 mg / ml to about 40 mg / ml of mannitol. (Item 12) 12. The pharmaceutical composition according to item 11, comprising about 23.8 mg / ml of mannitol. (Item 13) 12. The pharmaceutical composition according to item 11, comprising about 33.3 mg / ml of mannitol. (Item 14) 2. The pharmaceutical composition according to item 1, comprising about 1.0% to about 2.0% sucrose and about 2.0% (w / v) to about 4.0% (w / v) mannitol. (Item 15) 15. The pharmaceutical composition according to item 14, comprising about 1.2% (w / v) sucrose and about 2.4% (w / v) mannitol. (Item 16) 15. The pharmaceutical composition according to item 14, comprising about 1.7% (w / v) sucrose and about 3.3% (w / v) mannitol. (Item 17) 2. The pharmaceutical composition according to item 1, comprising about 10 mg / ml to about 20 mg / ml of sucrose and about 20 mg / ml to about 40 mg / ml of mannitol. (Item 18) 18. The pharmaceutical composition according to item 17, comprising about 11.9 mg / ml sucrose and about 23.8 mg / ml mannitol. (Item 19) 18. The pharmaceutical composition according to item 17, comprising about 16.7 mg / ml sucrose and about 33.3 mg / ml mannitol. (Item 20) 20. The pharmaceutical composition according to any one of items 1 to 19, comprising about 50 mM to about 60 mM NaCl. (Item 21) 21. The pharmaceutical composition of item 20, comprising about 55.6 mM NaCl. (Item 22) 20. The pharmaceutical composition according to any one of items 1 to 19, comprising about 3 mg / ml to about 4 mg / ml NaCl. (Item 23) 23. The pharmaceutical composition according to item 22, comprising about 3.25 mg / ml NaCl. (Item 24) 24. The pharmaceutical composition according to any one of items 1 to 23, comprising about 20 mM to about 40 mM L-histidine. (Item 25) 25. The pharmaceutical composition of claim 24, comprising about 25 mM L-histidine. (Item 26) 25. The pharmaceutical composition of item 24, comprising about 35 mM L-histidine. (Item 27) 24. The pharmaceutical composition according to any one of items 1 to 23, comprising about 3 mg / ml to about 6 mg / ml of L-histidine. (Item 28) 28. The pharmaceutical composition according to item 27, comprising about 3.88 mg / ml of L-histidine. (Item 29) 28. The pharmaceutical composition according to item 27, comprising about 5.43 mg / ml of L-histidine. (Item 30) 30. The pharmaceutical composition according to any one of items 1 to 29, comprising about 0.008% (w / v) to about 0.020% (w / v) of polysorbate 20 or polysorbate 80. (Item 31) 31. The pharmaceutical composition according to item 30, comprising about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 32) 31. The pharmaceutical composition according to item 30, comprising about 0.014% (w / v) of polysorbate 20 or polysorbate 80. (Item 33) 30. The pharmaceutical composition according to any one of items 1 to 29, comprising about 0.08 mg / ml to about 0.2 mg / ml of polysorbate 20 or polysorbate 80. (Item 34) 34. The pharmaceutical composition according to item 33, comprising about 0.10% mg / ml of polysorbate 20 or polysorbate 80. (Item 35) 34. The pharmaceutical composition according to item 33, comprising about 0.14 mg / ml of polysorbate 20 or polysorbate 80. (Item 36) 36. The pharmaceutical composition according to any one of items 1 to 35, wherein the rFIXFBP polypeptide is an rFIXFc polypeptide comprising a first subunit comprising an amino acid sequence that is at least 90% or 95% identical to amino acids 1 to 642 of SEQ ID NO: 2, and a second subunit comprising an amino acid sequence that is at least 90% to 95% identical to amino acids 1 to 227 of SEQ ID NO: 4. (Item 37) 37. The pharmaceutical composition according to item 36, wherein the rFIXFc polypeptide comprises a first subunit comprising amino acids 1 to 642 of SEQ ID NO: 2 and a second subunit comprising amino acids 1 to 227 of SEQ ID NO: 4. (Item 38) 38. The pharmaceutical composition according to any one of items 1 to 37, wherein the polypeptide having factor IX activity is present in a concentration of from about 25 IU / ml to about 1200 IU / ml. (Item 39) 39. The pharmaceutical composition of claim 38, comprising 50 IU / ml, 100 IU / ml, 200 IU / ml, 400 IU / ml, or 600 IU / ml of said rFIXFBP polypeptide. (Item 40) 40. The pharmaceutical composition of claim 39, comprising 50 IU / ml, 100 IU / ml, 200 IU / ml, or 400 IU / ml of said rFIXFBP polypeptide. (Item 41) 40. The pharmaceutical composition of item 39, comprising 600 IU / ml of said rFIXFBP polypeptide. (Item 42) (a) about 25 IU / ml to about 700 IU / ml of a rFIXFBP polypeptide; (b) about 1% (w / v) to about 2% (w / v) sucrose; (c) about 2% (w / v) to about 4% (w / v) mannitol; (d) about 50 mM to about 60 mM NaCl; (e) about 20 mM to about 40 mM L-histidine; (f) about 0.008% (w / v) to about 0.015% polysorbate 20 or polysorbate 80. (Item 43) (a) about 50 IU / ml of rFIXFBP polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 44) (a) about 100 IU / ml of a rFIXFBP polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 45) (a) about 200 IU / ml of a rFIXFBP polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 46) (a) about 400 IU / ml of a rFIXFBP polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 47) (a) about 600 IU / ml of a rFIXFBP polypeptide; (b) about 1.7% (w / v) sucrose; (c) about 3.3% mannitol; (d) about 55.6 mM NaCl; (e) about 35 mM L-histidine; (f) about 0.014% (w / v) of polysorbate 20 or polysorbate 80. (Item 48) (a) about 25 IU / ml to about 700 IU / ml of a rFIXFBP polypeptide; (b) about 10 mg / ml to about 20 mg / ml sucrose; (c) about 20 mg / ml to about 40 mg / ml of mannitol; (d) about 3 mg / ml to about 4 mg / ml NaCl; (e) about 3 mg / ml to about 6 mg / ml L-histidine; (f) about 0.08 mg / ml to about 0.15 mg / ml of polysorbate 20 or polysorbate 80. (Item 49) (a) about 50 IU / ml of rFIXFBP polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 50) (a) about 100 IU / ml of a rFIXFBP polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 51) (a) about 200 IU / ml of a rFIXFBP polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 52) (a) about 400 IU / ml of a rFIXFBP polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 53) (a) about 600 IU / ml of a rFIXFBP polypeptide; (b) about 16.7 mg / ml sucrose; (c) about 33.3 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 5.43 mg / ml L-histidine; (f) about 0.14 mg / ml of polysorbate 20 or polysorbate 80. (Item 54) (a) a first container containing a lyophilized powder, the powder comprising: (i) a rFIXFBP polypeptide; (ii) sucrose; (iii) mannitol, (iv) L-histidine, (v) a first container containing polysorbate 20 or polysorbate 80; (b) a second container comprising 0.325% (w / v) NaCl in combination with the lyophilized powder in the first container. (Item 55) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU of a rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 50 IU / ml of rFIXFBP polypeptide; (ii) about 1.2% (w / v) sucrose; (iii) about 2.4% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 25 mM L-histidine; and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 56) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 500 IU of a rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 100 IU / ml of a rFIXFBP polypeptide; (ii) about 1.2% (w / v) sucrose; (iii) about 2.4% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 25 mM L-histidine; and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 57) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 1000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 200 IU / ml of rFIXFBP polypeptide; (ii) about 1.2% (w / v) sucrose; (iii) about 2.4% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 25 mM L-histidine; and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 58) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 2000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 400 IU / ml of a rFIXFBP polypeptide; (ii) about 1.2% (w / v) sucrose; (iii) about 2.4% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 25 mM L-histidine; and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 59) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 3000 IU of rFIXFBP polypeptide; (i) about 83.3 mg of sucrose; (iii) about 167 mg of mannitol; (iv) about 27.2 mg of L-histidine; (v) a first container containing about 0.7 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 600 IU / ml of rFIXFBP polypeptide; (ii) about 1.7% (w / v) sucrose; (iii) about 3.3% (w / v) mannitol; (iv) about 55.6 mM NaCl; (v) about 35 mM L-histidine; and (vi) about 0.014% (w / v) polysorbate 20 or polysorbate 80, and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing (Item 60) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU of a rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 50 IU / ml of rFIXFBP polypeptide; (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; (vi) about 0.10 mg / ml of polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 61) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 500 IU of a rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 100 IU / ml of a rFIXFBP polypeptide; (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; (vi) about 0.10 mg / ml of polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 62) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 1000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 200 IU / ml of rFIXFBP polypeptide; (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; (vi) about 0.10 mg / ml of polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 63) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 2000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; (v) a first container containing about 0.50 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 400 IU / ml of a rFIXFBP polypeptide; (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; (vi) about 0.10 mg / ml of polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 64) (a) a first container containing a lyophilized powder, the powder comprising: (i) about 3000 IU of rFIXFBP polypeptide; (i) about 83.3 mg of sucrose; (iii) about 167 mg of mannitol; (iv) about 27.2 mg of L-histidine; (v) a first container containing about 0.7 mg of polysorbate 20 or polysorbate 80; (b) when combined with the lyophilized powder in the first container, (i) about 600 IU / ml of rFIXFBP polypeptide; (ii) about 16.7 mg / ml sucrose; (iii) about 33.3 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 5.43 mg / ml L-histidine; (vi) about 0.14 mg / ml of polysorbate 20 or polysorbate 80; and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (Item 65) 65. The kit of any one of items 54 to 64, wherein the first container is a glass vial with a rubber stopper. (Item 66) 66. The kit of any one of items 54 to 65, wherein the second container is a syringe body, the syringe body being associated with a plunger. (Item 67) Item 67. The kit of item 66, further comprising an adapter for connecting the glass vial to the syringe body. (Item 68) 68. The kit of claim 66 or 67, further comprising an injection tube associated with a needle connected to the syringe, suitable for intravenous injection. (Item 69) 54. A method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of prophylaxis, comprising administering intravenously to said subject the pharmaceutical composition according to any one of items 1 to 53 at an initial dose of about 50 IU / kg administered once a week, said administration preventing or reducing the frequency of bleeding episodes in said subject. (Item 70) 54. A method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of prophylaxis, comprising administering intravenously to the subject the pharmaceutical composition according to any one of items 1 to 53 at an initial dose of about 100 IU / kg administered once every 10 to 14 days, wherein said administration prevents or reduces the frequency of bleeding episodes in said subject. (Item 71) The method of claim 69 or 70, wherein the prophylactic dosage or dosing frequency is subsequently adjusted based on the subject's response. (Item 72) 73. A method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for mild to moderate bleeding episodes, comprising administering intravenously to said subject an initial dose of about 30 IU / kg to about 60 IU / kg of the pharmaceutical composition of any one of claims 1 to 53, wherein said administration controls, reduces or reverses said bleeding episodes. 73. The method of claim 72, further comprising administering one or more additional doses every 48 hours if the subject exhibits further signs of bleeding. (Item 74) 54. A method of administering an rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for a heavy bleeding episode, comprising administering intravenously to said subject a pharmaceutical composition according to any one of items 1 to 53 at an initial dose of about 100 IU / kg, said administration controlling, reducing or reversing said bleeding episode. (Item 75) 75. The method of claim 74, further comprising administering an additional dose of the pharmaceutical composition at about 80 IU / kg about 6 to 10 hours later if the bleeding episode continues. (Item 76) Item 77. The method of item 75, further comprising administering one or more additional doses of the pharmaceutical composition at 80 IU / kg every 24 hours for three days if the bleeding episode continues. 77. The method of claim 76, further comprising administering one or more additional doses of said pharmaceutical composition at about 80 IU / kg every 48 hours until said bleeding episodes are controlled. (Item 78) 54. A method for administering an rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, comprising administering intravenously a pharmaceutical composition according to any one of items 1 to 53 at a dose of about 50 IU / kg to 80 IU / kg to a subject with hemophilia B undergoing minor surgery, said administration controlling bleeding in said subject during and after surgery. (Item 79) 80. The method of claim 78, further comprising administering an additional dose of said pharmaceutical composition at about 50 IU / kg to 80 IU / kg about 24 to about 48 hours after surgery if necessary to control post-operative bleeding. (Item 80) 54. A method for administering an rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, comprising intravenously administering a pharmaceutical composition according to any one of items 1 to 53 at a dose of about 100 IU / kg to a subject with hemophilia B undergoing major surgery, said administration controlling bleeding in said subject during and after surgery. (Item 81) 81. The method of claim 80, further comprising administering an additional dose of said pharmaceutical composition at about 80 IU / kg about 6 to 10 hours later if necessary to control postoperative bleeding. (Item 82) 82. The method of claim 81, further comprising administering one or more additional doses of said pharmaceutical composition at 80 IU / kg every 24 hours for three days if necessary to control postoperative bleeding. (Item 83) 83. The method of claim 82, further comprising administering one or more additional doses of said pharmaceutical composition at about 80 IU / kg every 48 hours if necessary to control postoperative bleeding. (Item 84) The method according to any one of items 69 to 82, wherein the desired administration of the rFIXFBP polypeptide can be obtained from a single pharmaceutical kit according to any one of items 54 to 68. (Item 85) The method of any one of items 69 to 82, wherein the desired dose of the rFIXFBP polypeptide can be obtained from two or more pharmaceutical kits according to any one of items 54 to 68, and the contents of the two or more pharmaceutical kits are stored prior to administration. (Item 86) The rFIXFBP polypeptide has a mean T of about 70 hours to about 95 hours after a single intravenous infusion of 50 IU / kg of rFIXFBP. 1 / 2beta 54. The pharmaceutical composition according to any one of items 1 to 53, having (activity). (Item 87) The average T 1 / 2beta 54. The pharmaceutical composition according to any one of items 1 to 53, wherein the (activity) is about 82 hours. (Item 88) The average T 1 / 2beta 88. The pharmaceutical composition according to item 86 or item 87, wherein the activity is at least about 2-fold to about 3-fold higher than that of a polypeptide consisting of full-length mature factor IX (BENEFIX®) after a single intravenous infusion of 50 IU / kg of BENEFIX®. (Item 89) The average T 1 / 2beta 89. The pharmaceutical composition according to item 88, having an activity about 2.4 times higher than that of a polypeptide consisting of full-length mature factor IX (BENEFIX®). (Item 90) After a single intravenous infusion of 50 IU / kg of rFIXFc, the rFIXFc polypeptide has a mean C of about 30 IU / dL to about 50 IU / dL. max 90. The pharmaceutical composition according to any one of items 1 to 53 or 86 to 89, comprising: (Item 91) Said average C max is about 40.8 IU / dL. (Item 92) The pharmaceutical composition of any one of items 1-53 or 86-91, wherein after a single intravenous infusion of 50 IU / kg of rFIXFc, the rFIXFc polypeptide has a mean area under the curve per dose (AUC / dose) of about 27 IU*h / dL per IU / kg to about 35 IU*h / dL per IU / kg. (Item 93) 93. The pharmaceutical composition of item 92, wherein the mean AUC / dose is about 31.32 IU*h / dL per IU / kg. (Item 94) 94. The pharmaceutical composition of claim 92 or 93, wherein after a single intravenous infusion of 50 IU / kg of a polypeptide consisting of full-length mature factor IX (BENEFIX®), the mean AUC / dose is at least about 1.8- to about 2.1-fold higher than the polypeptide consisting of full-length mature factor IX (BENEFIX®). (Item 95) 95. The pharmaceutical composition of item 94, wherein the mean AUC / dose is about 1.99-fold higher than that of a polypeptide consisting of full-length mature factor IX (BENEFIX®). (Item 96) A method for reducing the annual bleeding rate in a subject with hemophilia B, comprising administering prophylactically, at regular or individualized dosing intervals, a fixed or individualized dose of the pharmaceutical composition according to any one of items 1 to 53 or items 86 to 95. (Item 97) 97. The method of claim 96, wherein the pharmaceutical composition is administered to the subject at a fixed dose and at fixed dosing intervals. (Item 98) 98. The method of claim 97, wherein the fixed dose of the pharmaceutical composition is about 50 IU / kg and the fixed administration interval is about one week. (Item 99) Item 98. The method of item 97, wherein the fixed dose of the pharmaceutical composition is about 100 IU / kg and the fixed administration interval is about 10 days to about 14 days. (Item 100) 97. The method of claim 96, wherein the pharmaceutical composition is administered to the subject in individualized doses at fixed dosing intervals. (Item 101) 101. The method of claim 100, wherein the fixed administration interval is about one week. (Item 102) The method according to item 100 or item 101, wherein the individualized dose is adjusted to achieve a plasma trough level of FIX activity of about 1 IU / dl to about 3 IU / dl. (Item 103) 103. The method according to any one of items 101 to 102, wherein the individualized dose is about 30 IU / kg to about 60 IU / kg and is administered about once a week. (Item 104) Item 104. The method of item 103, wherein the individualized dose is about 32 IU / kg to about 54 IU / kg and is administered about once a week. (Item 105) 105. The method of claim 104, wherein the average individualized dose is about 41 IU / kg and is administered about once a week. (Item 106) 106. The method according to any one of items 100 to 105, wherein the subject's annualized bleeding rate is reduced by about 70% to about 90% of the overall mean annualized bleeding rate of subjects with hemophilia B receiving treatment with episodic or on-demand administration. (Item 107) Item 107. The method according to Item 106, which reduces the annual bleeding rate of the subject by about 76% to about 89%. . (Item 108) 108. The method of claim 107, wherein the subject's annualized bleeding rate is reduced by about 83%. (Item 109) 97. The method of claim 96, wherein the pharmaceutical composition is administered to the subject in fixed doses at individualized dosing intervals. (Item 110) 110. The method of claim 109, wherein the fixed dose is about 100 IU / kg. (Item 111) The method of claim 109 or 110, wherein the individualized administration interval is adjusted to achieve a plasma trough level of FIX activity of about 1 IU / dl to about 3 IU / dl. (Item 112) 112. The method according to any one of items 109 to 111, wherein the individualized administration interval is from about 10 days to about 14 days. (Item 113) 13. The method of claim 112, wherein the individualized dosing interval is about 13 days. (Item 114) 114. The method of any one of items 109 to 113, wherein the subject's annualized bleeding rate is reduced by about 80% to about 95% of the overall mean annualized bleeding rate of subjects with hemophilia B receiving treatment with episodic or on-demand administration. (Item 115) The method according to Item 114, wherein the annual bleeding rate of the subject is reduced by about 80% to about 92%. (Item 116) 116. The method of claim 115, wherein the subject's annualized bleeding rate is reduced by about 87%. (Item 117) (a) about 25 IU / ml to about 700 IU / ml of an rFIX polypeptide; (b) about 1% (w / v) to about 2% (w / v) sucrose; (c) about 2% (w / v) to about 4% (w / v) mannitol; (d) about 50 mM to about 60 mM NaCl; (e) about 20 mM to about 40 mM L-histidine; (f) about 0.008% (w / v) to about 0.015% polysorbate 20 or polysorbate 80. (Item 118) (a) about 50 IU / ml of a FIX polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 119) (a) about 100 IU / ml of a FIX polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 120) (a) about 200 IU / ml of a FIX polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 121) (a) about 400 IU / ml of a FIX polypeptide; (b) about 1.2% (w / v) sucrose; (c) about 2.4% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 25 mM L-histidine; and (f) about 0.010% (w / v) of polysorbate 20 or polysorbate 80. (Item 122) (a) about 600 IU / ml of a FIX polypeptide; (b) about 1.7% (w / v) sucrose; (c) about 3.3% (w / v) mannitol; (d) about 55.6 mM NaCl; (e) about 35 mM L-histidine; (f) about 0.014% (w / v) of polysorbate 20 or polysorbate 80. (Item 123) (a) about 25 IU / ml to about 700 IU / ml of an rFIX polypeptide; (b) about 10 mg / ml to about 20 mg / ml sucrose; (c) about 20 mg / ml to about 40 mg / ml of mannitol; (d) about 3 mg / ml to about 4 mg / ml NaCl; (e) about 3 mg / ml to about 6 mg / ml L-histidine; (f) about 0.08 mg / ml to about 0.15 mg / ml of polysorbate 20 or polysorbate 80. (Item 124) (a) about 50 IU / ml of a FIX polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 125) (a) about 100 IU / ml of a FIX polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 126) (a) about 200 IU / ml of a FIX polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 127) (a) about 400 IU / ml of a FIX polypeptide; (b) about 11.9 mg / ml sucrose; (c) about 23.8 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 3.88 mg / ml L-histidine; (f) about 0.10 mg / ml of polysorbate 20 or polysorbate 80. (Item 128) (a) about 600 IU / ml of a FIX polypeptide; (b) about 16.7 mg / ml sucrose; (c) about 33.3 mg / ml mannitol; (d) about 3.25 mg / ml NaCl; (e) about 5.43 mg / ml L-histidine; (f) about 0.14 mg / ml of polysorbate 20 or polysorbate 80. (Item 129) 129. The pharmaceutical composition according to any one of items 117 to 128, wherein the FIX polypeptide is a long-acting FIX polypeptide. (Item 130) 129. The pharmaceutical composition of claim 128, wherein the long-acting FIX polypeptide comprises human FIX fused to an FcRn binding partner (rFIXFBP). (Item 131) 130. The pharmaceutical composition of item 129, wherein the FcRn binding partner is an Fc region. (Item 132) A method for reducing the annual bleeding rate in a subject with hemophilia B, comprising administering prophylactically, at regular or individualized dosing intervals, a fixed or individualized dose of the pharmaceutical composition according to any one of items 117 to 130. (Item 133) 131. The pharmaceutical composition according to any one of items 1 to 53, 86 to 95 and 117 to 130, further comprising a short-acting FIX polypeptide. (Item 134) 133. The pharmaceutical composition according to item 132, wherein the short-acting FIX polypeptide comprises or consists of wild-type FIX. (Item 135) 134. The pharmaceutical composition according to any one of items 1 to 53, 86 to 95, 117 to 130, and 132 to 133, which is a liquid formulation. (Item 136) 134. The pharmaceutical composition according to any one of items 1 to 53, 86 to 95, 117 to 130, and 132 to 133, which is a lyophilized powder. (Item 137) 134. The pharmaceutical composition according to any one of items 1 to 53, 86 to 95, 117 to 130, and 132 to 133, which is a suspension. (Item 138) 137. A vial comprising the pharmaceutical composition according to any one of items 134 to 136. (Item 139) A cartridge comprising the pharmaceutical composition according to item 134. (Item 140) A syringe comprising the pharmaceutical composition according to item 134 or item 135. (Item 141) Item 140. The syringe according to item 139, which is a dual chamber syringe. (Item 142) 69. The kit of any one of items 54-68, wherein the second container comprises a preservative in an amount sufficient to provide an antimicrobial effect. (Item 143) 135. The pharmaceutical composition of claim 134, wherein the solution further comprises a preservative in an amount sufficient to provide an antimicrobial effect. (Item 144) Item 141. The kit according to item 141 or the pharmaceutical composition according to item 142, wherein the preservative is selected from the group consisting of phenol, m-cresol, benzyl alcohol, chlorobutanol, methylparaben, propylparaben, phenoxyethanol, any other pharma- ceutically acceptable preservative, and any combination thereof. (Item 145) 144. The kit according to any one of items 141 or 143, or the pharmaceutical composition according to items 142 or 143, wherein the preservative is benzyl alcohol. (Item 146) Item 145. The kit or pharmaceutical composition according to item 144, wherein the benzyl alcohol is at a concentration of 0.5% to 0.9%. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0018] The present disclosure provides methods of treating FIX deficiency, such as hemophilia B, by administering a chimeric rFIXFBP polypeptide with an optimal formulation, optimal dosing interval, optimal dosing frequency, and / or optimal pharmacokinetic parameters. Also provided are formulations and pharmaceutical kits for administering rFIXFBP.

[0019] definition In this disclosure, the term "a" or "an" entity refers to one or more of that entity, for example, a "polynucleotide" is understood to refer to one or more polynucleotides. Thus, the terms "a" (or "an"), "one or more," and "at least one" may be used interchangeably herein.

[0020] Furthermore, "and / or" when used herein is to be interpreted as a specific disclosure of two particular features or components, each with or without the other feature or component. Thus, as used herein, the term "and / or" in a phrase such as "A and / or B" is intended to include "A and B," "A or B," "A" (single) and "B" (single). Similarly, the term "and / or" in a phrase such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C, A, B or C, A or C, A or B, B or C, A and C, A and B, B and C, A (single), B (single), and C (single).

[0021] As used herein, where an embodiment is described using the term "comprising," it should be understood that similar embodiments described using the terms "consisting of" and / or "consisting essentially of" are also provided.

[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press, The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press, and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press provide those of ordinary skill in the art with a general dictionary of many of the terms used in this disclosure.

[0023] Units, prefixes and symbols are those of the Systeme International The terms are presented in the format accepted by the United States Congress, International Standard Unites (SI). Numerical ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written from left to right in amino to carboxy orientation. The headings provided herein are not intended to limit the various aspects of this disclosure, which may be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined in their entirety by reference to the specification.

[0024] The term "about" is used herein to mean approximately, roughly, in the region of, or in the vicinity of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values ​​set forth. In general, the term "about" can modify the numerical value above and below the stated value by variances, for example, 10% above and below (higher or lower).

[0025] "Polypeptide," "peptide," and "protein" are used interchangeably to refer to a polymeric compound composed of covalently linked amino acid residues.

[0026] "Polynucleotide" and "nucleic acid" are used interchangeably and refer to a polymeric compound composed of covalently linked nucleotide residues. A polynucleotide can be DNA, cDNA, RNA, single-stranded or double-stranded, a vector, a plasmid, a phage, or a virus.

[0027] The term "administering" as used herein means, for example, prescribing or giving a pharmaceutical composition comprising a long-acting rFIXFBP polypeptide to a subject. Examples of routes of administration include, but are not limited to, intravenous injection, for example, via central venous access, and intravenous infusion. Further routes of administration include subcutaneous, intramuscular, oral, nasal, and pulmonary administration. A pharmaceutical composition comprising a long-acting rFIXFBP polypeptide may include one or more excipients as described herein. Advantages of the methods, compositions, and pharmaceutical kits provided herein include improved compliance, reduced breakthrough bleeding, improved protection of joints from bleeding, prevention of joint damage, reduced morbidity, reduced mortality, long-term protection from bleeding, reduced thrombotic events, and improved quality of life.

[0028] The term "rFIXFBP" or "rFIXFBP polypeptide" as used herein refers to a recombinant fusion protein comprising human coagulation factor IX (FIX) and an FcRn binding partner (rFIXFBP). Unless otherwise specified, FcRn binding partner ("FBP") includes a functional neonatal Fc receptor (FcRn) binding partner. An FcRn binding partner is any molecule that can be specifically bound by the FcRn receptor, resulting in active transport of the FcRn binding partner by the FcRn receptor. Thus, the term FcRn BP includes any variant of IgG Fc that is functional. For example, the region of the Fc portion of IgG that binds to the FcRn receptor has been described based on X-ray crystallography (Burmeister et al. 1994, Nature 1999). 372:379, incorporated herein by reference in its entirety). The major contact area of ​​Fc with FcRn is near the junction of the CH2 and CH3 regions. All of the Fc-FcRn contacts are within a single Ig heavy chain. FcRn BPs include whole IgG, Fc fragments of IgG, and other fragments of IgG that contain the complete binding region of FcRn. The major contact sites include amino acid residues 248, 250-257, 272, 285, 288, 290-291, 308-311, and 314 in the CH2 region, and amino acid residues 385-387, 428, and 433-436 in the CH3 region. All references made to the amino acid numbering of immunoglobulins or immunoglobulin fragments or regions are based on Kabat et al. 1991, Sequences of Proteins of Immunological Interest, USDepartment of Public Health, Bethesda; MD, which is incorporated herein by reference in its entirety. (FcRn receptors have been isolated from several mammalian species, including humans. The sequences of human FcRn, rat FcRn, and mouse FcRn are known (Story et al. 1994, J. Exp. Med. 180:2377), which are incorporated herein by reference in their entirety.) FcRn BPs may include immunoglobulin CH2 and CH3 regions with or without an immunoglobulin hinge region. Exemplary FcRn BP variants are provided in WO2004 / 101740 and WO2006 / 074199, which are incorporated herein by reference in their entirety.

[0029] In one embodiment, rFIXBP is rFIXFc, a recombinant fusion protein consisting of human coagulation factor IX (FIX) and the Fc region of human antigen (IgG1 isotype). See, for example, PCT Application No. PCT / US2011 / 043569, filed July 11, 2011, published as WO2012 / 006624, which is incorporated herein by reference in its entirety. The rFIXFc polypeptide is a heterodimeric protein that contains both a FIXFc single chain (FIXFc-sc) linkage and an Fc single chain (Fc-sc) linkage via two disulfide bonds in the hinge region of Fc. rFIXFc requires two protein subunits, FIXFc-sc (642 amino acids, SEQ ID NO:2) and Fc-sc (227 amino acids, SEQ ID NO:4), to assemble in transfected cell lines to form the final protein product, rFIXFc. The polynucleotide sequences encoding FIXFc-sc and Fc-sc are shown as SEQ ID NO:1 and SEQ ID NO:3, respectively.

[0030] The factor IX portion of rFIXFc has a primary amino acid sequence identical to the Thr148 allele of plasma-derived factor IX and has structural and functional characteristics similar to endogenous factor IX. The Fc region of rFIXFc contains the hinge, CH2, and CH3 regions of IgG1. The mature form of the assembled dimer of rFIXFc contains 869 amino acids with a molecular weight of approximately 98 kilodaltons.

[0031] rFIXFBP is produced in a human embryonic kidney (HEK) cell line by recombinant DNA technology. The cell line expresses rFIXFBP in a defined cell culture medium that does not contain any proteins from animal or human sources. rFIXFBP is purified by a series of chromatographic steps that do not require the use of monoclonal antigens. The process includes multiple virus removal steps, including 15 nm virus-trapping nanofiltration. No human or animal additives are used in the cell culture, purification, and formulation processes.

[0032] The terms "long-acting" and "long-lasting" are used interchangeably herein. In one embodiment, the term "long-acting" or "long-lasting" refers to FIX activity resulting from administration of an rFIXFBP polypeptide that is longer than the FIX activity of wild-type FIX (e.g., BENEFIX® or plasma-derived FIX ("pdFIX")). Any method known in the art can be used to measure "longer" FIX activity, such as aPTT assay, chromogenic assay, ROTEM, TGA, etc. In one embodiment, "longer" FIX activity refers to FIX activity that is longer than the FIX activity of wild-type FIX (e.g., BENEFIX® or plasma-derived FIX ("pdFIX")). 1 / 2beta In another embodiment, the "longer" FIX activity can be indicated by the level of FIX antigen present in plasma, e.g., T 1 / 2beta (antigen), can be inferred.

[0033] Factor IX clotting activity is expressed as International Unit(s) (IU). One IU of factor IX activity corresponds approximately to the amount of factor IX in one milliliter of normal human plasma. Several assays are available for measuring factor IX activity, including a one-stage clotting assay (activated partial thromboplastin time, or aPTT), thrombin generation time (TGA), and rotational thromboelastometry (ROTEM®).

[0034] The term "lyophilisate" or "lyophilisate" as used herein in connection with the formulations according to the invention refers to a formulation produced by the freeze-drying method essentially known in the art. The solvent (e.g. water) is removed by freezing followed by sublimation under vacuum and by desorption of the residual water at elevated temperature. In the field of formulations, lyophilisates usually have a residual moisture content of about 0.1% to 5% (w / w) and exist as a powder or a physically stable solid. Lyophilisates are characterized by a fast dissolution after the addition of a reconstitution solvent.

[0035] As used herein, the term "reconstituted formulation" refers to a formulation that has been lyophilized and reconstituted by the addition of a diluent, which can include, without limitation, water for injection (WFI), bacteriostatic water for injection (BWFI), sodium chloride solution (e.g., 0.9% (w / v) NaCl), glucose solution (e.g., 5% glucose), surfactant-containing solution (e.g., 0.01% polysorbate 20 or polysorbate 80), pH buffer (e.g., phosphate buffer), and combinations thereof.

[0036] As used herein, "dosing interval" refers to the time that elapses between multiple doses administered to a subject. Thus, the dosing interval may be presented as a range. The dosing interval of the rFIXFBP polypeptide in the methods provided herein may be at least 1.5 to 8 times longer than the dosing interval required for an equivalent amount (in IU / kg) of wild-type factor IX.

[0037] As used herein, the term "administration frequency" refers to the frequency with which a rFIXFBP polypeptide is administered over a period of time. The administration frequency can be expressed as the number of administrations per period of time, for example, once a week or once every two weeks.

[0038] As used herein, the term "prevention of one or more bleeding episodes" or "prophylactic treatment" refers to administering a rFIXFBP polypeptide to a subject in standard multiple doses over time to increase the level of factor IX activity in the subject's plasma and prevent bleeding episodes from occurring. In one embodiment, the term "prevention of one or more bleeding episodes" refers to using a rFIXFBP polypeptide to prevent or inhibit one or more sudden or uncontrollable bleeding or bleeding episodes, or to reduce the frequency of one or more sudden or uncontrollable bleeding or bleeding episodes. In another embodiment, the enhanced FIX activity level is sufficient to reduce the incidence of sudden bleeding or prevent bleeding in the event of an unexpected injury. Prophylactic treatment reduces or prevents bleeding episodes, e.g., bleeding episodes as described under on-demand treatment. Prophylactic treatment can be individually adjusted, e.g., to compensate for inter-subject variability, as described under "dosing intervals".

[0039] As used herein, the term "about once a week" means approximately and can include every 7 days ± 2 days, i.e., every 5 to 9 days. Thus, the administration frequency of "about once a week" can be every 5, 6, 7, 8, or 9 days.

[0040] As used herein, the term "individualized prophylactic interval" or "individualized prophylaxis" or "tailored prophylaxis" refers to the use of rFIXFBP polypeptides for individualized dosing intervals or frequencies to prevent or inhibit one or more spontaneous and / or uncontrollable bleeding or bleeding episodes, or to reduce the frequency of one or more spontaneous and / or uncontrollable bleeding or bleeding episodes. In one embodiment, an "individualized interval" includes every 10 days ± 3 days, i.e., every 7 to 13 days. Thus, the dosing frequency of an "individualized prophylactic interval" may be every 7 days, every 8 days, every 9 days, every 10 days, every 11 days, every 12 days, or every 13 days.

[0041] As used herein, "on-demand treatment" refers to treatment intended to be administered for a short period of time, in response to a current condition, such as a bleeding episode, or a predicted short-term need, such as a scheduled surgery. "On-demand treatment" is used interchangeably with "episodic" treatment. Conditions that may require on-demand treatment include bleeding episodes, hemarthrosis, muscle bleeds, oral bleeding, major bleeding, bleeding into muscle, major oral bleeding, trauma, head trauma, gastrointestinal bleeding, major intracranial bleeding, major intraperitoneal bleeding, major intrathoracic bleeding, fractures, central nervous system bleeding, retropharyngeal bleeding, retroperitoneal bleeding, or bleeding into the iliopsoas sheath. Other bleeding episodes are also included. The subject may require treatment for surgical prophylaxis, perioperative management, or surgery. Such procedures include minor surgery, major surgery, dental extractions, tonsillectomies, other dental / thoracic-facial surgeries, inguinal herniotomy, synovectomies, knee replacements, other joint replacement surgeries, craniotomies, osteosynthesis, trauma surgery, intracranial surgery, intraperitoneal surgery, intrathoracic surgery, and more.

[0042] Further conditions that may require on-demand treatment include minor bleeding, hemarthrosis, superficial muscle bleeding, soft tissue bleeding, moderate bleeding, intramuscular or soft tissue bleeding with dissection, mucosal bleeding, hematuria, major bleeding, pharyngeal bleeding, retropharyngeal bleeding, retroperitoneal bleeding, central nervous system bleeding, subcutaneous bleeding, cuts, abrasions, joint bleeding, nosebleeds, oral bleeding, gum bleeding, intracranial bleeding, intraperitoneal bleeding, spontaneous minor bleeding, bleeding after major trauma, moderate skin injury, or spontaneous bleeding into joints, muscles, internal organs, or the brain. Further reasons for on-demand treatment include the need for perioperative management of surgery or tooth extraction, major surgery, extensive oral surgery, urological surgery, hernia surgery, or orthopedic surgery such as replacement of the knee, hip, or other large joints.

[0043] As used herein, the term "treatment" or "treating" refers to the improvement or alleviation of one or more symptoms of a bleeding disease or disorder, including but not limited to hemophilia B. In one embodiment, "treatment" or "treating" of a bleeding disease or disorder includes the prevention of one or more symptoms of a bleeding disease or disorder. In a bleeding disease or disorder caused by FIX deficiency (e.g., low baseline FIX activity), the term "treatment" or "treating" can refer to FIX replacement therapy. By administering a FIXFc polypeptide to a subject, the subject can achieve and / or maintain a plasma trough level of FIX activity of about or greater than 1 IU / dl. In other embodiments, the term "treatment" or "treating" refers to the reduction in frequency of one or more symptoms of a bleeding disease or disorder, for example, spontaneous or uncontrollable bleeding episodes. However, "treatment" does not have to be a cure.

[0044] The term "perioperative management" as used herein refers to the use of a FIXFc polypeptide before, at the same time as, or after an operative procedure, e.g., a surgical procedure. The use of "perioperative management" of one or more bleeding episodes includes surgical prophylaxis before (i.e., pre-operative), during (i.e., intra-operative), or after (i.e., post-operative) surgery to prevent one or more bleeding or bleeding episodes, or to reduce or inhibit spontaneous and / or uncontrollable bleeding episodes before, during, and after surgery.

[0045] Pharmacokinetic (PK) parameters include the above and following terms that have their usual meaning in the art unless otherwise stated. Some terms are explained in more detail in the Examples. PK parameters can be based on FIX antigen levels (often parenthetically referred to herein as "antigen") or FIX activity levels (often parenthetically referred to herein as "activity"). In the literature, PK parameters are often based on FIX activity levels due to the presence in the plasma of some subjects of endogenous inactive FIX, which inhibits the ability to measure administered (i.e., exogenous) FIX using anti-FIX antibodies. However, when FIX is administered as part of an Fc fusion protein provided herein, administered (exogenous) FIX antigen can be accurately measured using an antibody against a heterologous polypeptide. Furthermore, certain PK parameters can be based on model predicted data (often parenthetically referred to herein as "model predicted") or observed data (often parenthetically referred to herein as "observed"), and are preferably based on observed data.

[0046] As used herein, the "baseline" is the lowest level of plasma factor IX measured in a subject prior to dosing. Factor IX plasma levels can be measured at two time points prior to dosing, i.e., at the screening visit and immediately prior to dosing. Alternatively, the baseline can be defined as 0% for (a) subjects with pretreatment FIX activity <1%, no detectable FIX antigen, and nonsense genotypes, (b) the baseline can be set at 0.5% for subjects with pretreatment FIX activity <1% and detectable FIX antigen, (c) the baseline can be set at Cmin (the lowest activity in the PK study) for subjects with pretreatment FIX activity 1-2%, and (d) the baseline can be set at 2% for subjects with pretreatment FIX activity ≥2%. Activity above the pretreatment baseline can be considered residual drug from previous treatment and can be reduced to baseline and subtracted from the PK data following rFIXFBP dosing.

[0047] As used herein, "T 1 / 2β " or "T1 / 2beta " or "Beta HL" is the elimination phase, t 1 / 2β = (In2) / half-life associated with the elimination rate constant associated with the terminal phase. T 1 / 2beta can be measured by FIX activity or FIX antigen levels in plasma. 1 / 2beta is T 1 / 2beta (active) and T based on FIX antigen levels 1 / 2beta is T 1 / 2beta (antigen). 1 / 2beta (active) and T 1 / 2beta Any of the (antigens) may be presented as a range or geometric mean.

[0048] As used herein, "trough" is the lowest plasma factor IX activity level reached after administration of a chimeric polypeptide of the invention or another factor IX molecule and before the next administration, if any. Trough is used herein synonymously with "threshold." The factor IX baseline level is subtracted from the measured factor IX level to calculate the trough level.

[0049] As used herein, the term "annualized bleeding rate" ("ABR") refers to the number of bleeding episodes (including spontaneous and traumatic bleeds) a subject experienced during a defined period estimated to be one year. For example, two bleeds within six months would indicate an ABR of four. The median ABR is provided as a single number to describe all subjects, indicating that half of the subjects had an individual ABR below the median and half had an ABR above the median.

[0050] As used herein, "subject" refers to a human. As used herein, subject includes individuals who have at least one incidence of uncontrolled bleeding episodes, for example, diagnosed with a bleeding disease or disorder, such as a disease or disorder associated with uncontrolled bleeding episodes of hemophilia B, known to be susceptible to uncontrolled bleeding episodes of hemophilia or any combination thereof. Subjects can also include individuals who are at risk of one or more uncontrolled bleeding episodes before a particular activity, for example, surgery, sports activity, or any vigorous activity. Subjects can have a baseline FIX activity of less than 1%, less than 0.5%, less than 2%, less than 2.5%, less than 3%, or less than 4%. Subjects also include children. Pediatric subjects are from birth to 20 years of age, preferably from birth to 18 years of age, from birth to 16 years of age, from birth to 15 years of age, from birth to 12 years of age, from birth to 11 years of age, from birth to 6 years of age, from birth to 5 years of age, from birth to 2 years of age, and from 2 to 11 years of age.

[0051] As used herein (interchangeably), "dose", "effective dose", or "administration" refers to a dose that achieves a plasma trough level of FIX activity of at least about 1 IU / dl or more than 1 IU / dl in a subject administered a FIXFc polypeptide. In one embodiment, "dose" refers to a dose that maintains a plasma trough level of FIX activity at or above about 1 IU / dl, at or above about 2 IU / dl, at or above about 3 IU / dl, at or above about 4 IU / dl, or at or above about 5 IU / dl throughout administration of the FIXFc polypeptide. In another embodiment, an "effective dose" reduces or decreases the frequency of bleeding or bleeding disorders. In another embodiment, an "effective dose" stops ongoing uncontrollable bleeding or bleeding episodes. In yet other embodiments, an "effective dose" prevents spontaneous bleeding or bleeding episodes in a subject susceptible to such episodes. A "therapeutic amount" need not cure hemophilia. Exemplary therapeutic amounts of rFIXFBP polypeptides in various bleeding situations are provided herein.

[0052] Factor IX Fc preparations The present disclosure provides a formulation or pharmaceutical composition comprising rFIXFBP.In the particular formulation provided herein, rFIXFBP is formulated as a sterile, preservative-free, non-pyrogenic, lyophilized, white to off-white powder to solid for intravenous (iv) administration.The formulation can be provided in a single-use vial.A particular exemplary formulation of rFIXFBP is also referred to as eftrenonacog alfa.

[0053] In certain embodiments, the rFIXFBP formulations are provided in single-use vials that are adapted to contain about 50 IU / ml, about 100 IU / ml, about 200 IU / ml, about 400 IU / ml, or about 600 IU / ml of rFIXFBP after reconstitution with an appropriate amount of diluent. In certain embodiments, where diluent is added to a final volume of about 5 ml, the single-use vials can typically contain about 250, about 500, about 1000, about 2000, or about 3000 International Units (IU) of rFIXFBP.

[0054] In certain embodiments, the rFIXFBP is rFIXFc. In some embodiments, the rFIXFc polypeptide comprises an amino acid sequence at least 90%, 95%, or 100% identical to amino acids 1-642 of SEQ ID NO:2.

[0055] In certain embodiments, the formulation comprises, in addition to active rFIXFBP, sucrose (which can function as a stabilizer or bulking agent), mannitol (which can function as a stabilizer or bulking agent), L-histidine (which can function as a buffering agent), and polysorbate 20 or polysorbate 80 (which can function as a stabilizer). A diluent comprising a sterile sodium chloride solution is provided with the formulation. In certain embodiments, the diluent is provided in a pre-filled syringe.

[0056] Thus, provided herein are pharmaceutical compositions that include a specific amount of rFIXFBP (in IU) along with the excipients sucrose, mannitol, L-histidine, NaCl, and polysorbate 20 or polysorbate 80. The compositions provided herein include various concentrations of various excipients, which concentrations can be indicated in various ways. For example, the concentration of a given excipient can be indicated as a molar concentration (e.g., M or mM), as a weight / volume percentage, e.g., grams per 100 ml of diluent, or as milligrams per milliliter (mg / ml). The formulations provided herein can include specific amounts of various excipients with precisions ranging from approximately, e.g., the concentration simply indicated, to one significant figure (e.g., about 0.1% (w / v)), or more precisely, e.g., 2, 3, 4, 5, or 6 significant figures (e.g., 3.88 mg / ml, which is precise to three significant figures). The degree of precision required may vary depending on, for example, the requirements of a given regulatory agency, or the manufacturing process. In certain embodiments, the pharmaceutical compositions may be provided as lyophilized forms, including reconstituted formulations with optional addition of diluents.

[0057] In certain embodiments, the pharmaceutical composition comprises about 25 IU / ml to about 1200 IU / ml of rFIXFBP, e.g., 50 IU / ml, 100 IU / ml, 200 IU / ml, 400 IU / ml, or 600 IU / ml of rFIXFBP. In certain embodiments, the pharmaceutical composition comprises 50 IU / ml, 100 IU / ml, 200 IU / ml, or 400 IU / ml of rFIXFBP in a formulation comprising about 3.88 mg / ml or 25 mM L-histidine, about 23.8 mg / ml or about 2.4% (w / v) mannitol, about 11.9 mg / ml or about 1.2% (w / v) sucrose, about 0.10 mg / ml or about 0.010% (w / v) polysorbate 20 or polysorbate 80, and about 3.25 mg / ml or about 55.6 mM NaCl.

[0058] In certain embodiments, the pharmaceutical composition comprises 600 IU / ml of rFIXFBP in a formulation comprising about 5.43 mg / ml or 35 mM L-histidine, about 33.3 mg / ml or about 3.3% (w / v) mannitol, about 16.7 mg / ml or about 1.7% (w / v) sucrose, about 0.14 mg / ml or about 0.014% (w / v) polysorbate 20 or polysorbate 80, and about 3.25 mg / ml or about 55.6 mM NaCl.

[0059] In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable amount of sucrose. In certain embodiments, the pharmaceutical composition comprises about 1% (w / v) to about 2% (w / v) sucrose, e.g., about 1.2% (w / v) sucrose or about 1.7% (w / v) sucrose. In certain related embodiments, the pharmaceutical composition comprises about 10 mg / ml to about 20 mg / ml sucrose, e.g., about 11.9 mg / ml sucrose or about 16.7 mg / ml sucrose.

[0060] In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable amount of mannitol. In certain embodiments, the pharmaceutical composition comprises about 2% (w / v) to about 4% (w / v) mannitol, e.g., about 2.4% (w / v) mannitol or about 3.3% (w / v) mannitol. In certain related embodiments, the pharmaceutical composition comprises about 20 mg / ml to about 40 mg / ml mannitol, e.g., about 23.8 mg / ml mannitol or about 33.3 mg / ml mannitol.

[0061] In certain embodiments, the pharmaceutical composition comprises sucrose and mannitol in pharma- ceutically acceptable amounts. In certain embodiments, the pharmaceutical composition comprises about 1.0% to about 2.0% sucrose and about 2.0% (w / v) to about 4.0% (w / v) mannitol, e.g., about 1.2% (w / v) sucrose and about 2.4% (w / v) mannitol, or about 1.7% (w / v) sucrose and about 3.3% (w / v) mannitol. In certain related embodiments, the pharmaceutical composition comprises about 10 mg / ml to about 20 mg / ml sucrose and about 20 mg / ml to about 40 mg / ml mannitol, e.g., about 11.9 mg / ml sucrose and about 23.8 mg / ml mannitol, or about 16.7 mg / ml sucrose and about 33.3 mg / ml mannitol. In certain embodiments, the sucrose and mannitol are provided as part of a lyophilizate that upon reconstitution with an appropriate amount of diluent provides the desired concentration of sucrose and mannitol.

[0062] In certain embodiments, the pharmaceutical composition comprises about 50 mM to about 60 mM NaCl, e.g., about 55.6 mM NaCl. In certain related embodiments, the pharmaceutical composition comprises about 3 mg / ml to about 4 mg / ml NaCl, e.g., about 3.25 mg / ml NaCl. In certain embodiments, NaCl is provided at the desired concentration in the diluent solution in which the lyophilisate comprising rFIXFBP is reconstituted.

[0063] In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable amount of L-histidine. In certain embodiments, the pharmaceutical composition comprises about 20 mM to about 40 mM L-histidine, e.g., about 25 mM L-histidine or about 35 mM L-histidine). In certain related embodiments, the pharmaceutical composition comprises about 3 mg / ml to about 6 mg / ml L-histidine, e.g., about 3.88 mg / ml L-histidine or about 5.43 mg / ml L-histidine. In certain embodiments, the L-histidine is provided as part of a lyophilizate that, upon reconstitution with an appropriate amount of diluent, provides the desired concentration of L-histidine.

[0064] In certain embodiments, the pharmaceutical composition comprises a pharma- ceutically acceptable amount of polysorbate 20 or polysorbate 80. In certain related embodiments, the pharmaceutical composition comprises about 0.008% (w / v) to about 0.020% (w / v) of polysorbate 20 or polysorbate 80, e.g., about 0.010% (w / v) of polysorbate 20 or polysorbate 80, or about 0.014% (w / v) of polysorbate 20 or polysorbate 80. In certain related embodiments, the pharmaceutical composition comprises about 0.08 mg / ml to about 0.2 mg / ml of polysorbate 20 or polysorbate 80, e.g., about 0.10% mg / ml of polysorbate 20 or polysorbate 80, or about 0.14 mg / ml of polysorbate 20 or polysorbate 80. In certain embodiments, polysorbate 20 or polysorbate 80 is provided as part of a lyophilizate that upon reconstitution with an appropriate amount of diluent provides a desired concentration of polysorbate 20 or polysorbate 80.

[0065] In one embodiment, the pharmaceutical composition comprises about 25 IU / ml to about 700 IU / ml of rFIXFBP polypeptide, about 1% (w / v) to about 2% (w / v) sucrose, about 2% (w / v) to about 4% (w / v) mannitol, about 50 mM to about 60 mM NaCl, about 20 mM to about 40 mM L-histidine, and about 0.008% (w / v) to about 0.015% polysorbate 20 or polysorbate 80. In certain embodiments, the pharmaceutical composition is provided as a lyophilisate or diluent. In certain embodiments, the amount of lyophilisate provides about 5 ml of a pharmaceutical composition containing the desired components at the desired concentrations.

[0066] In certain embodiments, the pharmaceutical composition comprises about 25 IU / ml to about 700 IU / ml of rFIXFBP polypeptide, about 10 mg / ml to about 20 mg / ml of sucrose, about 20 mg / ml to about 40 mg / ml of mannitol, about 3 mg / ml to about 4 mg / ml of NaCl, about 3 mg / ml to about 6 mg / ml of L-histidine, and about 0.08 mg / ml to about 0.15 mg / ml of polysorbate 20 or polysorbate 80. In certain embodiments, the pharmaceutical composition is provided as a lyophilisate or diluent. In certain embodiments, the amount of lyophilisate provides about 5 ml of a pharmaceutical composition containing the desired components at the desired concentrations.

[0067] Exemplary compositions are shown in Tables 1 and 2 in the Examples.

[0068] For example, the disclosure provides a pharmaceutical composition comprising about 50 IU / ml of rFIXFBP polypeptide, about 1.2% (w / v) sucrose, about 2.4% (w / v) mannitol, about 55.6 mM NaCl, about 25 mM L-histidine, and about 0.010% (w / v) polysorbate 20 or polysorbate 80. The disclosure further provides a pharmaceutical composition comprising about 100 IU / ml of rFIXFBP polypeptide, about 1.2% (w / v) sucrose, about 2.4% (w / v) mannitol, about 55.6 mM NaCl, about 25 mM L-histidine, and about 0.010% (w / v) polysorbate 20 or polysorbate 80. The disclosure further provides a pharmaceutical composition comprising about 200 IU / ml of a rFIXFBP polypeptide, about 1.2% (w / v) sucrose, about 2.4% (w / v) mannitol, about 55.6 mM NaCl, about 25 mM L-histidine, and about 0.010% (w / v) of polysorbate 20 or polysorbate 80. The disclosure further provides a pharmaceutical composition comprising about 400 IU / ml of a rFIXFBP polypeptide, about 1.2% (w / v) sucrose, about 2.4% (w / v) mannitol, about 55.6 mM NaCl, about 25 mM L-histidine, and about 0.010% (w / v) of polysorbate 20 or polysorbate 80. The disclosure further provides a pharmaceutical composition comprising about 600 IU / ml of rFIXFBP polypeptide, about 1.7% (w / v) sucrose, about 3.3% (w / v) mannitol, about 55.6 mM NaCl, about 35 mM L-histidine, and about 0.014% (w / v) polysorbate 20 or polysorbate 80.

[0069] The present disclosure further provides a pharmaceutical composition comprising about 50 IU / ml of rFIXFBP polypeptide, about 11.9 mg / ml of sucrose, about 23.8 mg / ml of mannitol, about 3.25 mg / ml of NaCl, about 3.88 mg / ml of L-histidine, and about 0.10 mg / ml of polysorbate 20 or polysorbate 80. The present disclosure further provides a pharmaceutical composition comprising about 100 IU / ml of rFIXFBP polypeptide, about 11.9 mg / ml of sucrose, about 23.8 mg / ml of mannitol, about 3.25 mg / ml of NaCl, about 3.88 mg / ml of L-histidine, and about 0.10 mg / ml of polysorbate 20 or polysorbate 80. The present disclosure further provides a pharmaceutical composition comprising about 200 IU / ml of rFIXFBP polypeptide, about 11.9 mg / ml of sucrose, about 23.8 mg / ml of mannitol, about 3.25 mg / ml of NaCl, about 3.88 mg / ml of L-histidine, and about 0.10 mg / ml of polysorbate 20 or polysorbate 80. The present disclosure further provides a pharmaceutical composition comprising about 400 IU / ml of rFIXFBP polypeptide, about 11.9 mg / ml of sucrose, about 23.8 mg / ml of mannitol, about 3.25 mg / ml of NaCl, about 3.88 mg / ml of L-histidine, and about 0.10 mg / ml of polysorbate 20 or polysorbate 80. The disclosure further provides a pharmaceutical composition comprising about 600 IU / ml of rFIXFBP polypeptide, about 16.7 mg / ml of sucrose, about 33.3 mg / ml of mannitol, about 3.25 mg / ml of NaCl, about 5.43 mg / ml of L-histidine, and about 0.14 mg / ml of polysorbate 20 or polysorbate 80.

[0070] The present disclosure also provides components of pharmaceutical kits. Such kits include one or more containers and optional accessories. The kits provided herein facilitate administration of an effective amount of rFIXFBP to a subject in need thereof. In certain embodiments, the kits facilitate administration of rFIXFBP by intravenous infusion. In certain embodiments, the kits facilitate self-administration of rFIXFBP by intravenous infusion.

[0071] In certain embodiments, the present disclosure provides a pharmaceutical kit comprising a first container containing a lyophilized powder or solid, the first container comprising (i) an rFIXFBP polypeptide, (ii) sucrose, (iii) mannitol, (iv) L-histidine, and (v) polysorbate 20 or polysorbate 80, and a second container containing a 0.325% (w / v) NaCl diluent solution combined with the lyophilized powder in the first container. In certain embodiments, sufficient diluent is provided to generate about 5 ml of an rFIXFBP formulation having the desired properties disclosed herein. In certain embodiments, the second container is a pre-filled syringe associated with a plunger, such that the diluent can be added to the first container to reconstitute the contents of the first container and place it back into the syringe. In certain embodiments, the kit further provides an adapter for attaching the syringe to the first container. In certain embodiments, the kit further provides a needle and injection tube that attaches to a syringe containing a reconstituted rFIXFBP formulation, allowing for intravenous injection of the formulation.

[0072] In certain embodiments, rFIXFBP is provided in a total amount of about 200 IU to about 4000 IU, for example, about 250 IU, about 500 IU, about 1000 IU, about 2000 IU, or about 3000 IU.

[0073] In one embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80; and when combined with the lyophilized powder in the first container, (i) about 50 IU / ml and (ii) about 1.2% (w / v) sucrose, (iii) about 2.4% (w / v) mannitol, (iv) about 55.6 mM NaCl, (v) about 25 mM L-histidine, and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80.

[0074] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 500 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 100 IU / mL. and (ii) about 1.2% (w / v) sucrose, (iii) about 2.4% (w / v) mannitol, (iv) about 55.6 mM NaCl, (v) about 25 mM L-histidine, and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80.

[0075] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 1000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 200 IU / mL. and (ii) about 1.2% (w / v) sucrose, (iii) about 2.4% (w / v) mannitol, (iv) about 55.6 mM NaCl, (v) about 25 mM L-histidine, and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80.

[0076] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 2000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 400 IU / mL. and (ii) about 1.2% (w / v) sucrose, (iii) about 2.4% (w / v) mannitol, (iv) about 55.6 mM NaCl, (v) about 25 mM L-histidine, and (vi) about 0.01% (w / v) polysorbate 20 or polysorbate 80.

[0077] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 3000 IU of rFIXFBP polypeptide; (ii) about 83.3 mg of sucrose; (iii) about 167 mg of mannitol; (iv) about 27.2 mg of L-histidine; and (v) about 0.7 mg of polysorbate 20 or polysorbate 80; and when combined with the lyophilized powder in the first container, (i) about 600 IU / m and (ii) about 1.7% (w / v) sucrose, (iii) about 3.3% (w / v) mannitol, (iv) about 55.6 mM NaCl, (v) about 35 mM L-histidine, and (vi) about 0.014% (w / v) polysorbate 20 or polysorbate 80.

[0078] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, is provided that, when combined with the lyophilized powder in the first container, (i) provides about 50 IU / ml of rFIXFBP polypeptide. A pharmaceutical kit is provided comprising an IXFBP polypeptide and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mt.ml L-histidine; and (vi) about 0.10 mg / ml polysorbate 20 or polysorbate 80.

[0079] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 500 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 100 IU / ml of rFIXFBP polypeptide. A pharmaceutical kit is provided comprising a FIXFBP polypeptide and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; and (vi) about 0.10 mg / ml polysorbate 20 or polysorbate 80.

[0080] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 1000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 200 IU / ml of rFIXFBP polypeptide. A pharmaceutical kit is provided comprising a FIXFBP polypeptide and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; and (vi) about 0.10 mg / ml polysorbate 20 or polysorbate 80.

[0081] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 2000 IU of rFIXFBP polypeptide; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 400 IU / ml of rFIXFBP polypeptide. A pharmaceutical kit is provided comprising a FIXFBP polypeptide and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; and (vi) about 0.10 mg / ml polysorbate 20 or polysorbate 80.

[0082] In a further embodiment, a first container containing a lyophilized powder, the powder comprising: (i) about 3000 IU of rFIXFBP polypeptide; (ii) about 83.3 mg of sucrose; (iii) about 167 mg of mannitol; (iv) about 27.2 mg of L-histidine; and (v) about 0.7 mg of polysorbate 20 or polysorbate 80, when combined with the lyophilized powder in the first container, (i) about 600 IU / ml of rFIXFBP polypeptide. A pharmaceutical kit is provided comprising a FIXFBP polypeptide and a second container containing 0.325% (w / v) NaCl in an amount sufficient to produce a solution containing: (ii) about 16.7 mg / ml sucrose; (iii) about 33.3 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 5.43 mg / ml L-histidine; and (vi) about 0.14 mg / ml polysorbate 20 or polysorbate 80.

[0083] In certain embodiments, the first container of the pharmaceutical kit provided herein is a glass vial with a rubber stopper.In certain embodiments, the pharmaceutical kit provided herein, the second container is a syringe body associated with a plunger.In certain embodiments, the syringe is a pre-filled syringe that includes a diluent.In certain embodiments, the pharmaceutical kit provided herein further comprises an adapter for connecting the glass vial to the syringe body.In certain embodiments, the pharmaceutical kit provided herein further comprises an injection tube associated with a needle that is connected to the syringe, suitable for intravenous injection.

[0084] In certain embodiments, the desired administration of rFIXFBP can be achieved by using one pharmaceutical kit provided herein. In certain embodiments, more than one pharmaceutical kit can be used to achieve the desired administration. Provided herein is a method for combining or storing the formulations contained in two or more pharmaceutical kits provided herein to achieve the desired administration.

[0085] Method of administration The present invention provides a method of administering rFIXFBP polypeptide to a human subject in need thereof, comprising administering to the subject a specific or scheduled dose of rFIXFBP polypeptide at a specific or scheduled administration interval. The administration of rFIXFBP polypeptide is a replacement therapy by adding recombinant FIX to a subject with FIX deficiency. The administration of rFIXFBP polypeptide can reduce or prevent the subject from bleeding or the number of bleeding episodes.

[0086] rFIXFBP is a long-acting antihemophilic factor (recombinant) indicated in adults and children (>= 12 years) with hemophilia B (congenital factor IX deficiency) for, e.g., control and prevention of bleeding episodes, routine prophylaxis to prevent or reduce the frequency of bleeding episodes, and perioperative management (surgical prophylaxis).

[0087] As used herein, a subject is a human subject who needs to control or prevent bleeding or bleeding episodes. The subject may bleed or be expected to bleed upon administration, or may be susceptible to bleeding in minor bleeding, hemarthrosis, superficial muscle bleeding, soft tissue bleeding, moderate bleeding, intramuscular or soft tissue bleeding with dissection, mucosal bleeding, hematuria, major bleeding, pharyngeal bleeding, retropharyngeal bleeding, retroperitoneal bleeding, central nervous system bleeding, subcutaneous bleeding, cuts, abrasions, joint bleeding, nosebleeds, oral bleeding, gum bleeding, intracranial bleeding, intraperitoneal bleeding, spontaneous minor bleeding, bleeding after major trauma, moderate skin injury, or spontaneous bleeding into joints, muscles, internal organs, or brain. Such subjects also include subjects who need perioperative management, such as, for example, management of bleeding associated with surgery or tooth extraction. In one embodiment, the subject needs prophylaxis of one or more bleeding episodes. In another embodiment, the subject needs individualized prophylactic intervals. In other embodiments, the subject needs on-demand treatment of one or more bleeding episodes. In yet other embodiments, the subject requires perioperative management of one or more bleeding episodes.

[0088] Provided herein are optimized and / or suitable doses and dosing intervals for use with the formulations, pharmaceutical compositions, and / or one or more pharmaceutical kits provided herein that can treat or prevent one or more bleeding episodes. By administering a suitable dose at a dosing interval, a plasma trough level of FIX activity of at least about 1 IU / dl or greater than 1 IU / dl can be achieved during the interval in subjects administered the rFIXFBP polypeptide. In one embodiment, the invention includes a dose (or range of doses) and dosing interval (or range of dosing intervals) that can maintain a plasma trough level of FIX activity of at least about or greater than 1 IU / dl (1%), at least about or greater than 2 IU / dl (2%), at least about or greater than 3 IU / dl (3%), at least about or greater than 4 IU / dl (4%), or at least about or greater than 5 IU / dl (5%) throughout the interval. In another embodiment, a dose (or range of doses) and dosing interval (or range of dosing intervals) that reduces or decreases the frequency of bleeding or bleeding disorders.

[0089] In certain embodiments, prophylactic treatment with rFIXFBP with a fixed dose at fixed intervals, a fixed dose at individualized intervals, an individualized dose at fixed intervals, or an individualized dose at individualized intervals can achieve a desired trough level of FIX activity.

[0090] In certain embodiments, a desired trough level of FIX activity can be achieved by prophylactically administering a fixed amount of rFIXFBP at fixed intervals. For example, rFIXFBP can be administered in an amount of about 50 IU / kg at intervals of about one week (e.g., every 7 days), or rFIXFBP can be administered in an amount of about 100 IU / kg at intervals of about 10 to about 14 days. In certain embodiments, the subject's trough level of FIX activity can be measured during the fixed dose and fixed interval schedule, and the dose and / or interval can be adjusted to achieve the desired trough level. In certain embodiments, the average individualized weekly dose for a group of subjects with hemophilia B is about 30 IU / kg to about 60 IU / kg, e.g., about 32 IU / kg to about 54 IU / kg, e.g., 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 56, 47, 48, 49, 50, 51, 52, 53, or 54 IU / kg, e.g., about 41 IU / kg. In certain embodiments, the average individual dosing interval for administration of 100 IU / kg is about 10 days to about 14 days, e.g., 10, 11, 12, 13, or 14 days, e.g., about 13 days.

[0091] In certain implementations, prophylactic administration of rFIXFBP may reduce a subject's annualized bleeding rate (ABR) by at least 70% below the average annualized bleeding rate of subjects treated with an episodic (on-demand) protocol.

[0092] In certain embodiments, subjects with hemophilia B are treated prophylactically with a fixed dose at fixed intervals, e.g., 50 IU / kg once a week, or 100 IU / kg once every 10, 11, 12, 13, or 14 days.

[0093] Subjects with hemophilia B are treated prophylactically with individualized doses at fixed intervals, e.g., about 30 IU / kg to about 60 IU / kg once a week, e.g., about 32 IU / kg to about 54 IU / kg once a week, e.g., 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 56, 47, 48, 49, 50, 51, 52, 53, or 54 IU / kg once a week, e.g., about 41 IU / kg once a week. In certain embodiments, the subject's ABR is reduced by about 70% to about 90%, e.g., the ABR is reduced by about 76% to about 89%, e.g., the ABR is reduced by about 70%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, or about 90%, e.g., the ABR is reduced by about 83%, as compared to the average ABR of episodic or on-demand treatment.

[0094] In certain embodiments where a subject with hemophilia B is prophylactically treated with a fixed dose at individualized intervals, e.g., about every 10 days to about every 14 days, e.g., about every 10 days, 11 days, 12 days, 13 days, or every 14 days, e.g., or about every 13 days, the subject's ABR is reduced by about 80% to about 95%, e.g., the ABR is reduced by about 80% to about 92%, e.g., the ABR is reduced by about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, about 91%, about 92%, about 93%, about 94%, or about 95%, e.g., a reduction of about 87%, as compared to the average ABR of episodic or on-demand treatment.

[0095] In certain embodiments, by prophylactically treating a subject with hemophilia B with rFIXFBP at fixed doses at fixed intervals, fixed doses at individualized intervals, individualized doses at fixed intervals, or individualized doses at individualized intervals, an ABR of less than 1, less than 2, less than 3, less than 4, or less than 5 bleeding episodes per year, e.g., from about 1 to about 5 bleeding episodes per year, can be achieved.

[0096] In other embodiments, the dose (or dose range) and dosing interval (or dosing interval range) of rFIXFBP polypeptide stops ongoing uncontrollable bleeding or bleeding episodes in a subject to whom the dose is administered during the dosing interval. In yet other embodiments, the dose (or dose range) and dosing interval (or dosing interval range) of rFIXFBP polypeptide prevents spontaneous bleeding or bleeding episodes in a subject susceptible to such episodes. Various doses and dosing intervals are described in International Application No. PCT / US2011 / 043569, filed July 11, 2011, and published January 12, 2012 as WO2012 / 006624, which is incorporated herein by reference in its entirety.

[0097] In one embodiment, the present disclosure provides a method of administering a rFIXFBP polypeptide to a subject with hemophilia B in need of prophylaxis, comprising administering to the subject intravenously a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein, at an initial dose of about 50 IU / kg administered about once per week, e.g., about once every 7 days, which can include every 6, 7, or 8 days. In accordance with this embodiment, this administration can prevent or reduce the frequency of bleeding episodes in the subject. In a further embodiment, the present disclosure provides a method of administering a rFIXFBP polypeptide to a subject with hemophilia B in need of prophylaxis, comprising administering to the subject intravenously a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein, at an initial dose of about 100 IU / kg administered about once every 10-14 days, e.g., about once every 10, 11, 12, 13, or 14 days. According to this embodiment, this administration can prevent or reduce the frequency of bleeding episodes in the subject.As a further embodiment of these methods, the prophylactic dose or frequency of administration can be adjusted based on the subject's response, for example, measured by one-stage coagulation (activated partial thromboplastin time, i.e., aPTT), thrombin generation time assay (TGA), or rotational thromboelastometry assay (ROTEM®).A person skilled in the art, for example, a physician who treats a subject with hemophilia B, can easily envision how or to what extent the subject's dose or frequency of administration should be adjusted to actively prevent and / or reduce the subject's bleeding episodes.

[0098] In one embodiment, the disclosure provides a method of administering rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for minor to moderate bleeding episodes, the method including administering to the subject intravenously an initial dose of about 30 IU / kg to about 60 IU / kg, e.g., 30 IU / kg, 40 IU / kg, 50 IU / kg, or 60 IU / kg, of a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein. According to this embodiment, this administration can control, reduce, or reverse the bleeding episode. The method can further include administering one or more additional doses if the subject shows further signs of bleeding, with a first additional dose administered about 48 hours later, and subsequent doses administered every 48 hours. According to this embodiment, administration can be continued until the bleeding episode subsides. One of skill in the art, for example a physician treating a subject with hemophilia B, can determine the initial dosage based on the severity of the bleeding episode, the subject's response, and on the level of FIX activity in the subject's blood.

[0099] In one embodiment, the disclosure provides a method of administering a rFIXFBP polypeptide to a subject with hemophilia B in need of treatment for a major bleeding episode, the method comprising administering intravenously to the subject an initial dose of about 100 IU / kg of a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein. According to this embodiment, this administration can control, reduce, or reverse the bleeding episode. The method can further comprise administering a booster dose of about 80 IU / kg about 6-10 hours later if the bleeding episode continues. The method can further comprise administering one or more booster doses of about 80 IU / kg about every 24 hours for three days if the bleeding episode continues. The method can further comprise administering one or more booster doses of 80 IU / kg every 48 hours until the bleeding episode is controlled. According to this embodiment, administration can be continued until the bleeding episode subsides.

[0100] In one embodiment, the disclosure provides a method of administering rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, the method including administering intravenously a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein, to a subject undergoing minor surgery, e.g., minor tooth extraction, at a dose of about 50 IU / kg to about 80 IU / kg, e.g., 50 IU / kg, 60 IU / kg, 70 IU / kg, or 80 IU / kg, administered at the time of surgery, e.g., before, simultaneously with, or after a minor surgical procedure. In accordance with this embodiment, this administration can control bleeding in the subject during and after surgery. The method can further include administering an additional dose of about 50 IU / kg to 80 IU / kg about 24 to about 48 hours after surgery, if necessary to control post-operative bleeding.

[0101] In one embodiment, the present disclosure provides a method of administering rFIXFBP polypeptide to a subject with hemophilia B in need of surgical prophylaxis, the method including administering a pharmaceutical composition disclosed herein, e.g., a pharmaceutical composition reconstituted from one or more pharmaceutical kits provided herein, intravenously to a subject undergoing major surgery at a dose of about 100 IU / kg administered at the time of surgery, e.g., before, simultaneously with, or after the major surgical procedure. In accordance with this embodiment, this administration can control bleeding in the subject during and after surgery. Major surgery can include, but is not limited to, total knee replacement, arthroscopic procedures, e.g., arthroscopic knee fusion, rectal fistula closure, external knee fusion, tendon transfer, incision and drainage of dental abscess with tooth extraction, incision and drainage of pilonidal cyst, debridement, partial amputation, or finger amputation. The method can further include administering an additional dose of about 80 IU / kg about 6-10 hours later if necessary to control postoperative bleeding. The method can further include administering one or more additional doses of about 80 IU / kg about every 24 hours for three days if the bleeding episode continues. The method can further include administering one or more additional doses of 80 IU / kg every 48 hours until the bleeding episode is controlled. According to this embodiment, administration can be continued until the bleeding episode subsides.

[0102] In one aspect, the present disclosure provides pharmacokinetic parameters of the pharmaceutical compositions provided herein compared to commercially available rFIX (a polypeptide consisting of full-length mature factor IX, e.g., BENEFIX®).

[0103] In one embodiment, the pharmaceutical compositions provided herein provide a mean T of about 70 hours to about 95 hours after a single intravenous infusion of 50 IU / kg of rFIXFBP. 1 / 2beta (activity), e.g., the mean T 1 / 2beta In certain embodiments, the pharmaceutical compositions provided herein administered as a single intravenous infusion of 50 IU / kg of BENEFIX® followed by a single intravenous infusion of 50 IU / kg of rFIXFBP have a mean T 1 / 2beta (activity) that is at least about 2-fold to about 3-fold higher than BENEFIX®, e.g., an average T 1 / 2beta (activity) is approximately 2.4 times higher than BENEFIX®.

[0104] In one embodiment, following a single intravenous infusion of about 50 IU / kg of rFIXFBP, the pharmaceutical compositions provided herein provide a mean C max , for example, about 40.8 IU / dL. In one embodiment, after a single intravenous infusion of 50 IU / kg of rFIXFBP, the pharmaceutical compositions provided herein have a mean area under the curve per dose (AUC / dose) of about 27 IU*h / dL per IU / kg to about 35 IU*h / dL per IU / kg, for example, about 31.32 IU*h / dL per IU / kg. In a particular embodiment, after a single intravenous infusion of 50 IU / kg of BENEFIX®, the pharmaceutical compositions provided herein administered as a single intravenous infusion of 50 IU / kg of rFIXFBP have a mean AUC / dose that is at least about 1.8-fold to about 2.1-fold, for example, about 1.99-fold higher than BENEFIX®.

[0105] In certain embodiments of the invention, the methods of the invention further comprise measuring a baseline level of FIX activity in the subject prior to the initial administration of rFIXFBP polypeptide. Measuring the baseline level of FIX activity can employ any coagulation assay known in the art, such as a one-stage aPTT assay, a two-stage chromogenic assay, ROTEM, TGA, etc.

[0106] In some embodiments, the methods of the invention include administering a rFIXFBP polypeptide to a subject, followed by administration of the rFIXFBP polypeptide. 1 / 2beta (active) or T 1 / 2beta It further includes measuring (antigen).

[0107] Having now described the invention in detail, it will be more clearly understood by reference to the following examples, which are included herewith for illustrative purposes only and are not intended to limit the invention. All patents and publications mentioned herein are expressly incorporated by reference. EXAMPLES

[0108] Example 1: Product Description rFIXFc is a long-acting, fully recombinant fusion protein consisting of human coagulation factor IX (FIX) covalently linked to the Fc region of human immunoglobulin G1 (IgG1). The factor IX portion of rFIXFc is the Thr2 domain of plasma-derived factor IX. 148 It has a primary amino acid sequence identical to the allelic variant and has structural and functional characteristics similar to endogenous factor IX. The Fc region of rFIXFc contains the hinge, CH2 and CH3 regions of IgG1. rFIXFc contains 869 amino acids with a molecular weight of approximately 98 kilodaltons.

[0109] rFIXFc is produced by recombinant DNA technology in an extensively characterized human embryonic kidney (HEK) cell line. The cell line expresses rFIXFc into a defined cell culture medium that is free of any proteins from animal or human sources. rFIXFc is purified by a series of chromatographic steps that do not require the use of monoclonal antigens. The process includes multiple virus removal steps, including 15 nm virus-trapping nanofiltration. No human or animal additives are used in the cell culture, purification, and formulation processes.

[0110] rFIXFc is in the drug therapy group, namely, hemostatic drugs B02BD04. It is formulated as a sterile, preservative-free, non-pyrogenic, lyophilized, white to off-white powder to solid for intravenous (IV) administration in a single-use vial with a liquid diluent in a pre-filled syringe. In addition to rFIXFc, the pharmaceutical composition contains sucrose, L-histidine, mannitol, and polysorbate 20 in lyophilisate, and in a sterile solvent sodium chloride solution (0.325%). Each single-use vial contains nominally 250, 500, 1000, 2000, or 3000 international units (IU) of rFIXFc. When reconstituted with the diluent provided, the product contains the following excipients: sucrose, sodium chloride, L-histidine, mannitol, and polysorbate 20, in the concentrations shown in Table 1 or Table 2 below. The pharmaceutical composition is formulated for intravenous administration only after reconstitution.

[0111] Each pack contains a powder vial (Type 1 glass) with a stopper (butyl) and flip-off seal (aluminum), 5 ml of solvent in a pre-filled syringe (Type 1 glass) with a plunger stopper (butyl), a tip cap (butyl), and a sterile vial adapter reconstitution device. [Table 1] [Table 2]

[0112] Example 2: Formulation Method The rFIXFc drug product is a sterile, injectable, lyophilized powder intended for intravenous administration. It is supplied in sterile filled, single-use vials containing nominal doses of 250, 500, 1000, 2000, and 3000 IU per vial. The vials are 10 mL USP / ph. Eur. Type 1 glass vials sealed with 20 mm Teflon-coated butyl rubber lyophilization stoppers and aluminum flip-off corrugated seals. Prior to lyophilization, the nominal fill volume targets for the 250-2000 IU vials are 5 mL and for the 3000 IU vials 7 mL. The composition of formulation excipients prior to lyophilization is the same for all dosage strengths. The powder for injection is reconstituted with 5 mL of diluent containing 0.325% (w / v) sodium chloride supplied in a sterile prefilled syringe.

[0113] The composition of the drug product solution before lyophilization is shown in Table 3, and the composition of the lyophilized powder is shown in Table 4. The composition of the drug product after reconstitution is shown in Table 1 or Table 2. (Example 1). [Table 3] [Table 4]

[0114] Administration can be carried out by attaching a syringe to a standard intravenous infusion tube / needle in place and delivering rFIXFc intravenously in standard manner known to those of skill in the art.

[0115] Example 3: Dosage and Method of Administration / How to Calculate the Estimated Initial Dose rFIXFc is a long-acting antihemophilic factor (recombinant) indicated in adults and children (>= 12 years) with hemophilia B (congenital factor IX deficiency) for, e.g., control and prevention of bleeding episodes, routine prophylaxis to prevent or reduce the frequency of bleeding episodes, and perioperative management (surgical prophylaxis).

[0116] Dosing of rFIXFc formulated as described in Example 1 can be estimated as described in this example, but can also be determined by standard tests such as, for example, the FIX activity assay described elsewhere herein.

[0117] One IU of rFIXFc per kg of body weight is predicted to increase serum factor IX levels by 1% [IU / dL]. rFIXFc has been shown to have a long circulating half-life.

[0118] Generally, no dose adjustment for recovery is necessary. Because subjects may vary in their pharmacokinetics (e.g., half-life, in vivo recovery) and clinical response to rFIXFc, the expected in vivo peak rise or required dose of Factor IX, expressed as IU / dL (or % of normal), can be estimated using the following formula: IU / dL (or % of normal) = [total dose (IU) / body weight (kg)] x recovery (IU / dL for every IU / kg) or Dose (IU) = body weight (kg) × desired factor IX increase (IU / dL or % of normal) × reciprocal of recovery (IU / kg for every IU / dL)

[0119] The following table (Table 5) can be used to guide dosing during bleeding episodes. [Table 5]

[0120] Subsequent doses and treatment times will be determined according to individual clinical response, the severity of the factor IX deficiency, and the location and extent of the bleeding (see pharmacokinetics in Example 5 below).

[0121] The following table (Table 6) can be used to guide dosing and perioperative management (surgical prophylaxis): [Table 6]

[0122] The recommended starting dose for routine prophylaxis is either 50 IU / kg once per week or 100 IU / kg once every 10-14 days, either dose can be adjusted based on subject response (pharmacokinetics, see Example 5 below).

[0123] rFIXFc is contraindicated in subjects who have had a history of severe hypersensitivity reactions, including anaphylaxis, to the product or its components.

[0124] Clinical response to rFIXFc may vary. If bleeding is not controlled at the recommended dose, the plasma level of factor IX may be determined and a sufficient dose of rFIXFc may be administered to achieve a good clinical response. If the subject's plasma factor IX level does not rise as expected after administration of rFIXFc or if bleeding is not controlled, the subject's plasma may be tested for the presence of inhibitors, such as neutralizing antibodies. The development of factor IX inhibitors in subjects using rFIXFc may be monitored by appropriate clinical observations and clinical tests known to those skilled in the art.

[0125] If clinically indicated, the subject's plasma factor IX activity levels can be monitored, for example, by performing a one-stage clotting assay to ensure that adequate factor IX levels are achieved and maintained. The development of factor IX inhibitors in the subject's plasma can further be monitored.

[0126] Example 4: B-LONG Study Design The study design is a global, open-label, multicenter, Phase 3 study.

[0127] The objective was to evaluate the efficacy and safety of intravenously infused controlled recombinant factor IX Fc fusion protein (rFIXFc) for the prevention of bleeding episodes, routine prophylaxis, and perioperative management in individuals with severe hemophilia B.

[0128] Key study inclusion criteria were: (a) male, (b) age >12 years, (c) diagnosed with severe hemophilia B defined as endogenous factor IX activity of 2% (≤2 IU / dL FIX:C), and (d) with a history of ≥100 prior documented days of exposure to currently marketed FIX products.

[0129] Treatment arms included arm 1 (weekly prophylaxis), arm 2 (individualized interval prophylaxis), arm 3 (episodic [on-demand] treatment), and arm 4 (perioperative management).

[0130] In arm 1 (weekly prophylaxis), subjects were treated with an initial dose of 50 IU / kg weekly, which was subsequently adjusted to maintain trough factor levels sufficient to prevent bleeding.

[0131] Under arm 2 (individualized prophylaxis interval), subjects were treated with 100 IU / kg at an initial interval of 10 days, which was then adjusted to maintain trough factor levels sufficient to prevent bleeding.

[0132] Under arm 3 (episodic [on-demand] treatment), subjects received episodic treatment of rFIXFc for bleeding as needed.

[0133] In arm 4 (perioperative management), rFIXFc was administered before and after major surgery; if a subject required surgery during the study, during the perioperative period, the subject could enter directly into the surgery arm and then cross into one of the post-operative treatment arms (arm 1, arm 2, or arm 3) or cross into the surgery arm from another arm.

[0134] For PK assessment, all subjects in all arms had an initial PK assessment after the first dose of rFIXFc. A subset of subjects from arm 1 was assigned to a protocol-specific sequential PK subgroup to compare the PK of FIXFc with recombinant factor IX (rFIX, BENEFIX®) as follows: (1) prior to treatment in arm 1, PK was assigned after a single dose of BENEFIX® at 50 IU / kg. PK was then assessed in these same subjects after a single dose of rFIXFc at 50 IU / kg, and (2) the PK of rFIXFc was repeated at week 26. The primary efficacy outcome measures included: (1) annualized bleeding rate (ABR) in arms 1, 2, and 3 ((i) the weekly prophylaxis arm compared to the episodic treatment arm, and (ii) the individualized prophylaxis interval arm compared to the episodic treatment arm); (2) the number of injections required to stop a bleeding episode; and (3) the subject's response to surgery with rFIXFc as assessed by the treating physician using a 4-point scale.

[0135] Pharmacokinetic (PK) outcome measures include the PK of rFIXFc and recombinant factor IX (rFIX, BENEFIX®).

[0136] The primary safety outcome measures included (a) incidence of inhibitory factor growth and (b) incidence of adverse events (AEs) occurring outside the intraoperative management arms (arms 1, 2, and 3, but not including 4).

[0137] B-LONG result subject The safety, efficacy, and pharmacokinetics of rFIXFc were evaluated in a multicenter, open-label, prospective study comparing the efficacy of two respective prophylactic treatment regimens against episodic (on-demand) treatment, efficacy of a defined hemostatic agent in the treatment of bleeding episodes, and efficacy of a defined hemostatic agent during perioperative management in subjects undergoing major surgical procedures. A total of 123 previously treated subjects (PTPs) aged 12-71 years with severe hemophilia B (≤2% endogenous FIX activity) were studied for up to 77 weeks. 93.5% of subjects completed the study, with 115 subjects receiving treatment for at least 26 weeks and 56 subjects receiving treatment for at least 52 weeks.

[0138] Sixty-three (63) subjects in the fixed weekly interval arm began receiving rFIXFc for routine prophylaxis at an initial dose of 50 IU / kg. Dose was adjusted to maintain troughs above baseline or at 1-3% as high as clinically needed to prevent bleeding. For the 58 subjects who were on study for at least 9 months, the median weekly dose during the final 6 months on study was 40.7 IU / Kg (interquartile range, 32.3, 54.1).

[0139] Twenty-nine (29) subjects in the individualized interval arm received rFIXFc at a dose of 100 IU / kg every 10 days for routine prophylaxis, with the interval adjusted to maintain troughs above baseline or 1 to 3% as high as clinically needed to prevent bleeding. For the 26 subjects who had been on study for at least 9 months, the median interval during the last 6 months was 13.8 days (interquartile range, 10.5, 14.0).

[0140] Twenty-seven (27) subjects received rFIXFc for treatment of bleeding episodes as needed in the episodic (on-demand) treatment arm.

[0141] Twelve (12) subjects received rFIXFc for perioperative management in 14 major surgical procedures. Four subjects did not participate in the other arm.

[0142] Effectiveness of routine prevention Compared with the episodic (on-demand) treatment arm based on a negative binomial model, annualized bleeding rate (ABR) was reduced by 83% (76%-89%) in subjects in the fixed weekly interval arm and by 87% (80%-92%) in subjects in the individualized interval arm.

[0143] The median treatment time in the study was 51.4 weeks (range, <1 to 77). Comparisons of ABR in subjects evaluable for efficacy are summarized in Table 7. [Table 7]

[0144] Effectiveness in controlling bleeding A total of 636 bleeding events were observed in the fixed-dose, fixed-interval, and episodic (on-demand) arms. Evaluation of the response to each infusion was recorded by the subject 8-12 hours after treatment. The bleeding episodes are summarized in Table 8. [Table 8]

[0145] Effectiveness in intraoperative management (surgical prophylaxis) Fourteen (14) major surgical procedures were performed in 12 subjects. Hemostasis was assessed 24 hours postoperatively by the investigator using a 4-point scale of excellent, good, fair, poor, and none. Hemostatic response was assessed as excellent or good in 100% of major procedures. There was no clinical evidence of thrombotic complications in any subject. Hemostatic response to intraoperative and postoperative administration is summarized in Table 9. [Table 9]

[0146] Impact on quality of life Quality of life was measured using the HAEM-A-QoL, a hemophilia-specific quality of life assessment instrument. The HAEM-A-QoL was administered to adults (ages 18 years and older) in the prophylactic treatment arm. Changes from baseline at week 26 in the combined prophylaxis arm according to prestudy medication are summarized in Table 10. [Table 10]

[0147] The median dosing interval in the individualized prophylaxis interval arm was 14 days during the last 6 months on study.

[0148] Control of bleeding: More than ninety percent (90.4%) of bleeding episodes were controlled by a single infusion of rFIXFc.

[0149] Intraoperative Management: Treating physicians rated the hemostatic effectiveness of rFIXFc as very good or good in 100% of procedures.

[0150] Adverse drug reactions (ADRs) were reported in 10 of 119 (8.4%) subjects treated with routine prophylaxis or episodic (on-demand) treatment. Adverse drug reactions are adverse events considered by the investigator as related or possibly related to treatment with rFIXFc. Adverse drug reactions are summarized in Table 11.

[0151] No subjects withdrew from the study due to adverse drug reactions. No inhibitors were detected and no anaphylactic events were reported in the study. [Table 11]

[0152] Example 5: Pharmacology and Pharmacokinetics Pharmacology rFIXFc is a long-acting, fully recombinant fusion protein that temporarily replaces the deficient coagulation factor IX required for effective hemostasis. rFIXFc contains the Fc region of human immunoglobulin G1 (IgG1) that binds to the neonatal Fc receptor (FcRn), which is part of a naturally occurring pathway that delays lysosomal degradation of immunoglobulins by circulating them back into the blood circulation and is responsible for their prolonged plasma half-life.

[0153] rFIXFc is a long-acting, fully recombinant fusion protein containing human coagulation factor IX (FIX) covalently linked to the Fc region of human immunoglobulin G1 (lgG1) and produced by recombinant DNA technology.

[0154] Factor IX (FIX) is a vitamin K-dependent serine protease of approximately 55 kDa that is an essential clotting factor in the coagulation cascade that is important in the hemostatic process. FIX is normally converted to activated FIX (FIXa) by the activated factor VII / tissue factor complex, or activated factor XI. FIXa forms a complex with activated factor VIII on a phospholipid surface, which converts factor X to activated factor X and finally prothrombin to thrombin, leading to the formation of a fibrin clot.

[0155] Subjects with hemophilia B lack functional FIX, which leads to prolonged bleeding after trauma and spontaneous rebleeding into soft tissues and joints. The FIX portion of rFIXFc has structural and functional characteristics similar to endogenous FIX and promotes hemostasis by correcting the functional FIX defect.

[0156] The other part of rFIXFc is the human immunoglobulin G1 (IgG1) Fc region, which binds to the neonatal Fc receptor (FcRn) that has been shown to be part of a naturally occurring pathway throughout life that protects immunoglobulins from lysosomal degradation by circulating immunoglobulin proteins back into the blood circulation, thereby prolonging their plasma half-life.

[0157] rFIXFc is used as replacement therapy to increase plasma levels of factor IX activity, which may temporarily correct the factor deficiency and correct the bleeding tendency.

[0158] Hemophilia B is a bleeding disorder characterized by a deficiency of functional coagulation factor IX (FIX), which results in prolonged clotting times in the activated partial thromboplastin time (aPTT) assay, a traditional in vitro test for FIX bioactivity. Treatment with rFIXFc can shorten the aPTT over an effective period of administration.

[0159] Pharmacokinetics The pharmacokinetics (PK) of rFIXFc versus BENEFIX® [nonacog alfa] (rFIX) was evaluated in 22 evaluable subjects (>= 19 years) from a clinical study after a 10 minute intravenous infusion. Subjects underwent a 5 day washout period before receiving 50 IU / kg BENEFIX®. PK sampling was performed pre-dose followed by post-dose evaluations at 8 time points up to 96 hours. After a 120 hour (5 day) washout period, subjects received a single dose of rFIXFc at 50 IU / kg. PK samples were collected pre-dose followed by post-dose evaluations at 11 time points up to 240 hours (10 days). PK evaluation of rFIXFc was repeated at week 26.

[0160] PK parameters of rFIXFc were assessed based on plasma FIX activity over time profile. For FIXFc, maximum activity (Cmax) was observed immediately after infusion, i.e., 10 minutes after the start of dosing. The geometric mean increase in circulating FIX activity from pre-infusion levels was 0.92 IU / dL per IU / kg, with an elimination half-life of 82 hours. This half-life was influenced by the Fc region of rFIXFc, which has been shown in animal models to be mediated by the FcRn circulating pathway. The rFIXFc PK profile was stable over repeated dosing, as shown by comparable PK parameters at week 26.

[0161] A summary of the PK parameters of rFIXFc and BENEFIX® is shown in Table 12. [Table 12]

[0162] A population PK model was developed based on PK data from 135 subjects (12 Phase 1 / 2a and 123 Phase 3 subjects) aged 12-76 years and weighing 45 kg-186.7 kg in two clinical studies. Population evaluations showed that the typical CL of rFIXFc was 2.39 dL / h, the typical volume of the central compartment (V1) was 71.4 dL, and the Vss was 198.3 dL. The geometric mean terminal half-life of rFIXFc was approximately 82 hours, which is 2.4-fold longer than that of BeneFIX® (approximately 34 hours).

[0163] All subjects were a representative population of subjects with hemophilia B and had an initial PK evaluation to characterize the PK of rFIXFc.

[0164] More extensive PK sampling was performed in a subset of subjects in the baseline weekly prophylaxis arm (arm 1) after a single dose of BeneFIX® at 50 IU / kg followed by a single dose of rFIXFc at 50 IU / kg. Blood samples were taken for BeneFIX® over a 96 hour period. Blood samples were taken for rFIXFc over a 240 hour period. PK assessment of rFIXFc was repeated at week 26.

[0165] The 100-IU / kg dose was selected based on PK results from a phase 1 / 2 study, which showed that this dose elevated FIX levels to approximately 100% of normal (Shapiro et al 2011). In a phase 1 / 2 study with rFIXFc at 100 IU / kg (n=5), the time to reach FIX levels 1% above baseline was approximately 11 days, varying from 9 to 14 days. Based on these data, arm 2 was designed to test whether a fixed dose of 100 IU / kg could provide protection from bleeding for more than 1 week.

[0166] The terminal half-life of BeneFIX® determined by B-LONG of approximately 34 hours is longer than the terminal half-life reported in the BeneFIX® package insert (~18 hours) as well as the terminal half-life reported in several studies that followed EMA guidelines for PK evaluation of FIX using a 48 hour sample duration (13.7-19.3 hours) (Ewenstein 2002, Kisker et al. 2003, Negrier et al. 2011). However, published PK studies in which BeneFIX® was sampled up to 72 hours after dosing also reported longer half-lives of 21.3-33.4 hours (Ragni et al. 2002, Lambert et al. 2007, Chang et al. 2007, and Martinowitz et al. 2012).

[0167] To determine any differences in the half-life of BeneFIX® resulting from the longer PK sampling schedule of 96 hours employed in this study, the PK data for BeneFIX® were also analyzed using data only up to 48 hours post-dose. This analysis yielded a significantly shortened terminal half-life for BeneFIX® (~17 hours), which is consistent with previous reports using a sampling duration of 48 hours.

[0168] In the B-LONG study, a direct comparison was made between rFIXFc and BeneFIX®, while in the Phase 1 / 2 study, the half-life of rFIXFc was compared to historical data reported in the BeneFIX® Product Insert (2009). Therefore, the B Long study's measurement of PK improvement of rFIXFc over BeneFIX® is more reliable and accurate.

[0169] The foregoing description of specific embodiments will make fully apparent the general nature of the present invention, such that others may, by applying knowledge within the skill of those of ordinary skill in the art, without undue experimentation, readily modify and / or adapt such specific embodiments for various applications without departing from the general concept of the present invention. Such adaptations and modifications are therefore intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology used herein is for purposes of description and not of limitation, as the terminology or terminology used herein would be interpreted by one of ordinary skill in the art in light of the teaching and guidance.

[0170] Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.

Claims

1. 1. A pharmaceutical kit for use in the treatment of hemophilia B in a subject in need thereof, comprising: (a) a first container containing a lyophilized powder, the powder comprising: (i) about 250 IU, about 500 IU, about 1000 IU, about 2000 IU, about 3000 IU, or about 4000 IU of a recombinant Factor IX ("rFIXFc") polypeptide comprising human Factor IX fused to the Fc domain of a human antibody; (ii) about 59.5 mg of sucrose; (iii) about 119 mg of mannitol; and (iv) about 19.4 mg of L-histidine; and (v) about 0.50 mg of polysorbate 20; and A first container comprising: (b) a second container containing a 0.325% (w / v) NaCl solution in an amount sufficient to produce the following solution when combined with the lyophilized powder in the first container: (i) about 50 IU / ml, about 100 IU / ml, about 200 IU / ml, about 400 IU / ml, about 600 IU / ml, or about 800 IU / ml of an rFIXFc polypeptide; (ii) about 11.9 mg / ml sucrose; (iii) about 23.8 mg / ml mannitol; (iv) about 3.25 mg / ml NaCl; (v) about 3.88 mg / ml L-histidine; and (vi) about 0.10 mg / ml of polysorbate 20; and a second container comprising: A pharmaceutical kit comprising:

2. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 250 IU of rFIXFc polypeptide and said solution comprises 50 IU / ml of rFIXFc polypeptide.

3. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 500 IU of rFIXFc polypeptide and said solution comprises 100 IU / ml of rFIXFc polypeptide.

4. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 1000 IU of rFIXFc polypeptide and said solution comprises 200 IU / ml of rFIXFc polypeptide.

5. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 2000 IU of rFIXFc polypeptide and said solution comprises 400 IU / ml of rFIXFc polypeptide.

6. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 3000 IU of rFIXFc polypeptide and said solution comprises 600 IU / ml of rFIXFc polypeptide.

7. 2. The pharmaceutical kit for use according to claim 1, wherein said lyophilized powder comprises 4000 IU of rFIXFc polypeptide and said solution comprises 800 IU / ml of rFIXFc polypeptide.

8. The pharmaceutical kit for use according to any one of claims 1 to 7, wherein the first container is a glass vial with a rubber stopper.

9. The pharmaceutical kit for use according to any one of claims 1 to 8, wherein the second container is a syringe body, the syringe body being associated with a plunger.

10. 10. The pharmaceutical kit for use according to any one of claims 1 to 9, wherein the second container contains 5 ml of a 0.325% (w / v) NaCl solution.

11. 11. The pharmaceutical kit for use according to any one of claims 1 to 10, wherein the rFIXFc polypeptide comprises a first subunit comprising an amino acid sequence at least 95% identical to amino acids 1 to 642 of SEQ ID NO:2 and a second subunit comprising an amino acid sequence at least 95% identical to amino acids 1 to 227 of SEQ ID NO:

4.

12. 12. The pharmaceutical kit for use according to any one of claims 1 to 11, wherein the rFIXFc polypeptide comprises a first subunit comprising amino acids 1 to 642 of SEQ ID NO:2 and a second subunit comprising amino acids 1 to 227 of SEQ ID NO:

4.

13. 13. The pharmaceutical kit for use according to claim 11 or claim 12, wherein the first subunit and the second subunit are linked via two disulfide bonds in the hinge region of Fc.

Citation Information

Patent Citations

  • Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity

    JP2002513390A

  • Sodium chloride solution for drug reconstitution or dilution

    JP2009513705A

  • Stabilized factor IX preparation containing trehalose

    JP2011507871A

  • Stable compositions of factor ix

    WO2011104552A1

  • Factor ix polypeptides and methods of use thereof

    WO2012006624A2